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Abstract
There is a clear need for the development of novel materials for bone regeneration. There is, 
however, with the exception of poly-(methyl methacrylate) a lack of mouldable polymeric fillers 
for irregular bone defects.  In this thesis, we investigate the production of a new bone graft 
replacement combining magnetite nanoparticles with polycaprolactone (PCL) to produce a 
material that can soften in response to the application of an alternating magnetic field. The 
magnetite nanoparticles were synthesized by a non-surfactant method and then emulsified with 
PCL.  Particle size analysis using light scattering showed that the size distributions of magnetite 
nanoparticles were influenced by acid concentration and mixing conditions.  In contrast, the size 
of the PCL particles were not strongly related to the mixing conditions, but was influence by the 
stabilizer used during emulsification.  
 
The magnetite nanoparticles showed superparamagnetic behaviour when analysed using SQUID. 
In the thermal test, magnetite nanoparticles display smooth curves both in the heating and cooling 
processes and do not shows significant heat loss.  Scanning electron microscopy and chemical 
analysis showed that the magnetite nanoparticles were evenly distributed through the polymer 
matrix and could be caused to melt following an appropriate external magnetic stimulus.  It was 
demonstrated that magnetite containing microspheres could successful be used for the 
encapsulation and delivery of antibiotics at a dose which was sufficient to be lethal to E. coli. 
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Chapter 1 Introduction 
As the mean age of the population increases, there is a growing need for new methods to 
regenerate diseased and damaged bone (Braddock et al., 2001).  The current most frequently used 
approach to fill bone defects is the tissue graft, which can be harvested from the patient 
(autograft), a cadaver (allograft) or an animal (xenograft) (Kawamura and Urist, 1988; Teixeira 
and Urist, 1998), (Murray et al., 1993) before implantation.  Numerous problems, however, are 
associated with each of these approaches.  In the case of autografts, the harvesting procedure can 
be traumatic and can result in a range of complications including pain, morbidity and gait 
disturbance (Schmelzeisen et al., 2003).  Allografting is associated with some major ethical 
issues (Stock and Vacanti, 2001) and bone xenografts are not typically used in the UK due to 
concerns with interspecies disease transmission (Teixeira and Urist, 1998).  These problems have 
stimulated research into the development of new treatment methods utilising synthetic materials, 
which may be applied with or without cells and other temperature sensitive therapeutic molecules. 
Polymeric materials, in particular, have been investigated widely for this purpose.  Examples of 
polymeric materials previously investigated for use as bone graft replacements include: alginate, 
chitosan, gelatin, hyaluronic acid (HA), poly-(ethylene glycol) (PEG), poly-(ε-caprolactone) 
(PCL) and poly-(L-lactic acid) (PLLA) (Rezwan et al., 2006)   
 
PCL is not cytotoxic, is of relatively low cost and can degrade over a period of years in the body. 
It has been suggested that electrospun PCL is a potential candidate scaffold for bone tissue 
engineering (Sinha et al., 2004).  As PCL can soften at relatively low temperatures (45 ºC to 60 
ºC), it has been proposed that it can be used to deliver a range of heat sensitive therapeutic 
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entities (cells, proteins) that may be effective in stimulating new bone formation.  To date, 
however, without directly heating the polymer outside the body prior to application, nobody has 
reported a method that allows PCL to be moulded to irregular defects (Coombes et al., 2004; 
Abukawa et al., 2006). One possible approach could be the generation of heat by an immobilised 
particulate, such as nanomagnetite, which has been used in many medical applications and is 
accepted in body (Matsura et al., 2004; Ito et al., 2004).  
 
 
 
Figure 1.1 Nanoscale magnetite was encapsulated within a polymeric matrix, 
which was subsequently melted in an alternating magnetic field. The softened 
material could be moulded into irregular defects. 
 
The objective of this study was to process microspheres of poly-(caprolactone) containing nano-
scale magnetite. As shown in Figure 1.1, when placed in a magnetic field the local production of 
heat by the magnetite particles may cause the PCL to soften.  Once softened, the magnetite/PCL 
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(MP) microspheres can be deformed and moulded into irregular defects such as those 
encountered in a wide range of bone traumas.  
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Chapter 2 Bone and bone replacements 
2.1 Bone replacements 
Bone, to a certain extent, may repair itself following injury. However, certain diseases and 
treatments may result in extensive bone-loss. In these cases, a bone graft may be employed with 
the aim to: fill the bone defects (preventing fibrous ingrowth), stimulate bone growth and play a 
structural role (Froum et al., 2002). In the United Kingdom, health care is alone set to cost over 
£900 million and this cost will rise with an increasing ageing population, each year (Chrischilles 
et al., 1994). Due to osteoporosis, there are 150,000 fractures (wrist, vertebral and hip) in the UK, 
each year (Reeve and Metz, 1998). Moreover, an estimated 500,000 to 600,000 bone grafting 
procedures are performed annually in the United States (Bucholz, 2002). In 2007, a leading bone 
grafting materials company reported sales over 700 million dollars in the US, and the global 
orthobiologics market was reported that which worth nearly US$3.1 billion in 2009 (Krohn, 2008, 
Espicom Business Intelligence, 2010). 
 
Over all, synthetic bone grafts have numerous advantages  over tissue grafts including unlimited 
supply, easy sterilization and storage. Furthermore, tissue grafts are associated with poor 
handling properties, variable rates of resorption, poor performance in diaphyseal defects and 
potentially adverse effects on normal bone remodeling (Bucholz, 2002). Autografts lack 
sufficient availability, may be of poor quality, and result in trauma to the donor site. The use of 
allograft is associated with ethical issues and can also result in disease transmission. Disease 
transmission is also the main problem associated with xenografts (Teixeira and Urist, 1998; 
Patience et al., 1997).  
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2.2 Tissue grafting replacements 
The problems associated with bone tissue grafting have driven research to develop new synthetic 
materials, to replace bone with ceramics, cements, metals and polymers. In addition, there is a 
growing need for bone regeneration due to bone infections, bone tumors and bone loss by trauma. 
The materials may or may not be absorbable, and can be naturally derived materials or synthetic 
materials, such as polymers. Recent research has primarily focused on biodegradable and 
biocompatible materials; both naturally derived and synthetic (Burg et al., 2000, Braddock et al., 
2001, Stevens et al., 2008).  
 
2.2.1 Currently used biodegradable materials 
Currently used biomaterials for resorbable bone replacements could be classified into three types: 
ceramics, hydrogels and synthetic polymers. 
 
Ceramics 
Ceramics have been commonly used for bone replacements as they can have a composition 
similar to bone and may be osteoconductive. There are several types of ceramic materials, such as, 
alumina, calcium sulphate hemihydrate, bioglass and calcium phosphates. The most widely 
studied calcium phosphate ceramics include ß tricalcium phosphate (ß-TCP), hydroxyapatite (HA) 
and biphasic calcium phosphate (BCP) (Hollinger and Battistone, 1986; Burg et al., 2000; Grover 
et al., 2006).  
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Hydrogels 
Hydrogels are an appealing material because they are structurally similar to the extracellular 
matrix of many tissues. The formation of hydrogels occurs under relatively mild conditions, and 
they may be delivered in a minimally invasive manner. Novel methods to control material 
degradation have been engineered into many hydrogels. Furthermore, hydrogels encapsulating 
cells have been applied for regeneration of skin, bone and many different types of tissues (Hunt 
and Grover, 2010). Several naturally derived materials may be used to form hydrogels, including 
agarose, alginate, chitosan, collagen, fibrin, gelatine, and hyaluronic acid (Drury and Mooney, 
2003, Seol et al., 2004, Xiong et al., 2001).  
 
The term alginate refers to a family of polyanionic copolymers derived from brown sea algae and 
comprises 1,4-linked β–D-mannuronic (M) and α–L-guluronic (G) residues in varying 
proportions. Sodium alginate is soluble in aqueous solutions and forms stable gel at room 
temperature. It has found biomedical and biotechnology applications mainly as a material for 
encapsulation and immobilisation of a variety of cells for immunoisolatory and biochemical 
processing applications (Drury and Mooney, 2003, Wang et al., 2003).  
 
Chitosan is a biodegradable natural polymer that has been shown to improve wound healing. It 
can be produced in various forms including film, sponge and its degradation rate can be 
controlled. It is a 1,4 linked 2-amino-2-deoxy-β-D-glucan derived from chitin, poly-β-(1→4)-N-
acetyl-D-glucosamine, and therefore the biologic origin of the aminopolysaccharide allows 
multiple bioactivites, for example, low toxicity, biocompatibility, biodegradability, antimicrobial, 
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and wound-healing properties (Drury, and Mooney, 2003; Lee et al., 2000; Seol et al., 2004; Yin 
et al., 2003). In vitro investigation demonstrated that chitosan sponges support the differentiation 
of seeded osteoblastic cells as well as their proliferation (Seol et al., 2004).  
 
Gelatin is obtained through a controlled denaturation of the fibrous insoluble protein collagen, a 
major component of skin, bone and connective tissue. It displays several attractive qualities: It 
does not show antigenicity or resorbability in vivo and its physicochemical properties may be 
suitably modulated (Yin et al., 2003). 
 
Hyaluronic acid is a linear polysaccharide composed of a repeating disaccharide. It is a simple 
glycosaminoglycan (GAG) and is found in nearly every mammalian tissue and fluids. It is 
especially prevalent during wound healing and in the synovial fluid of joints and usually 
degraded by hyaluronicdase, allowing cells in the body to regulate the clearance of the material in 
a localized manner (Drury and Mooney, 2003). 
 
Synthetic Polymers 
Synthetic polymers are commonly used for bone replacement.  The local tissue responses to 
polymers in vivo depend on the biocompatibility of the polymer as well as the by-products of its 
degradation (Hollinger and Battistone, 1986). Diverse types of polymer have been widely used in 
biomaterial engineering to form scaffolds in the form of sponges and nanofibres (Ikada, 2006). 
Furthermore, polymers can be easily formed into polymer-based biocomposites with other type of 
materials. For example, nano-hydroxyapatite (NHAP) and composite scaffolds may serve as an 
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excellent 3D substrate for cell attachment and migration in bone regeneration and tissue 
engineering. (Burg et al., 2000, Wei and Ma, 2004).  
 
There are various kinds of polymeric materials for bone replacements and their modes of 
application depend on the resultant structures and physiochemical properties. For example, 
biodegradable and absorbable polymeric fillers will disappear over time, or porous scaffold allow 
room for bone growth into the scaffold constructs.  Polymers are also used for the delivery of 
cells and other therapeutic entities.  Therapeutic objects are added into polymeric carriers prior to 
implantation.  For instance, polymeric sponges are used to grow osteoblasts in a 3D structure for 
transplantation into a site for bone regeneration (Lee et al., 2000). There is some research focused 
on developing nanomaterial for tissue or bone replacements, such as nanofibre fabrication and 
nanopolymers. These kinds of materials supply highly porous microstructures for cell 
attachments and migration to better mimic the natural bone (Wei and Ma, 2004, Yashimoto et al., 
2003). 
 
Some widely used polymeric materials for bone replacements include polyether (such as poly-
ethylene glycol (PEG)) and polyester (such as poly-caprolactone (PCL) and poly-L-lactic acid 
(PLA)); use depends on different purposes and methods of application (Yoon and Fisher et al., 
2006).  For example, PLA satisfies many biomaterial requirements, such as controlled porous 
architecture, and appropriate mechanical properties, and has been used as a scaffold for 
engineering. It is one of the biodegradable polymers and has been demonstrated to be 
biocompatible and degrade into non-toxic components with a controllable degradation rate in 
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vivo (Xiong et al., 2001, Wei and Ma, 2004, Gross and Rodriguez-Lorenzo, 2004). In addition, 
PCL is a polymer lacking toxicity, is of low cost and degrades at an appropriate rate. It has been 
suggested that electrospun PCL is a potential candidate scaffold for biomaterial and tissue 
engineering (Hutmacher, 2000). One researcher reported that while the relatively high transition 
temperature of PCL (65 °C) is likely to have a beneficial effect on the structural integrity of the 
scaffold, the key different can be attributed to the processing methods and resulting different 
structures (Yashimoto et al., 2003).  
 
2.3 BMPs/osseoactive factors or growth factors and drug delivery 
Bone morphogenetic protein (BMP) is a group of proteins responsible for a variety of events in 
embryogenesis and in the postnatal skeleton. BMPs have been shown to play a role in 
embryological bone formation, osteo-induction, and bone repair as well as the possibility that 
they may assist in the replacement of autogenous bone graft (Drury and Mooney, 2003). 
Osteoblast transplantation using polymers scaffolds is a promising strategy that may overcome 
the limitations of traditional bone graft materials (Wang et al., 2003, Seol et al., 2004). There are 
some growth factors and cells that can be used in tissue repair, e.g. stem cells and fibroblasts, 
have been applied as drug delivery systems in bone replacements. The use of growth factors has 
the potential to markedly increase scaffold effectiveness (Rosa et al., 2004; Yashimoto et al., 
2003). 
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Chapter 3 Polycaprolactone 
3.1 General physicochemical properties 
Researchers have investigated the use of poly-caprolactone (PCL) for 80 years; and many of its  
physicochemical properties, such as biodegradability, drug permeability, non-toxicity, were 
established between the 1930s and 1970s (Sinha et al., 2004). PCL exhibits a molecular weight 
from 1000 to over 100,000 which affects the properties of resultant products (Chen et al., 1998; 
Fields et al., 1974; Tang et al., 2004). PCL’s melting point (Tm) is dependent on Mw and can 
range from 45 ºC to 60 ºC, it usually has a glass transition temperature (Tg) around -60 ºC and 
biodegrades in a period from weeks to years. The degradation of PCL in human body may be 
affected by molecular weight, crystallinity, environment and temperature (37 ºC). (Ali et al., 
1993; Coombes et al., 2004).  
 
O
O
caprolactone
O
O
catalyst
 
Figure 3.1 Initiation of open-ring polymerization in the monomer of PCL. 
 
Caprolactone monomers are polymerized to form polycaprolactone of different molecular weight 
and copolymers via a ring opening polymerization as shown in Figure 3.1. PCL presents good 
solubility in organic solvents, such as dichloromethane, toluene and chloroform. PCL is a semi-
crystalline polymer and has a high permeability due to its low Tg point, which makes PCL a 
potential candidate in drug delivery and tissue engineering. The crystallinity of PCL is affected 
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by temperature and the chemical production in the environment (Pitt et al., 1979; Parthiban et al., 
2010).        
 
3.2 PCL based biomaterials and their composites 
Polymers can be formulated into spheres, which have attracted huge interest from researchers as 
they can be used to synthesis supports for cell growth and tissue replacement (Abukawa et al., 
2006).  Advantages of PCL includes low cost, slow degradation and biocompatibility, a variety of 
products of PCL composites are formed by combining drug, cell and several biomaterials 
(Williams et al., 2005).  PCL composites can be simply divided into two categories, PCL based 
biomaterials and as therapeutic carriers; and many processing methods can be used to synthesise 
a range of PCL composites. 
  
3.2.1 PCL based biomaterials 
Much research has been undertaken with composites of PCL and other materials to enhance 
stress crack resistance and compatibility.  To broaden the field of application of PCL, structure 
and chemistry can be varied by altering process methods (Parthiban et al., 2010). Rearrangement 
of polymer chain structures has been investigated by using different catalyst methods and varying 
the temperature and time of the polymerization process. Copolymers of PCL in diblock and 
triblock with poly (D,L-lactide) (PLA), poly (hydroxyl acids) (PHA) and other polyesters were 
reported to improve mechanical properties, enables some control over degradation rate and 
allows manipulation of structural shape (Pitt et al., 1981; Ural et al., 2000).  
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The production of covalently attached inorganic substances enabled the fabrication of a range of 
tissue engineering scaffolds and drug delivery systems (Rhee, 2003). For example, PCL 
covalently bonded to silica has been shown to initiate apatite formation and enables good bone 
attachment in vitro. Hydroxyapatite (HA) and other calcium phosphate based materials are often 
used to form a composite with PCL, because of their chemical similarity to natural bone and 
osteoconductivity (Kim et al., 2004
1
; Yang et al., 2008). Moreover, PCL particles on the 
nanoscale have been of interest in developing drug delivery and targeting systems by 
encapsulating magnetite, which has been used in PCL applications not only in tissue engineering 
but also in pharmaceutics and tumor therapy (Kim et al., 2002). 
 
3.2.2 Therapeutic carrier   
Pharmaceutical application of PCL has attracted a great deal of interest in therapeutic substance 
delivery due to its high permeability and biodegradability. Porous PCL scaffolds are popular 
candidates for delivering of drugs, growth factors and proteins, and preventing fibrous tissue 
ingrowth while providing an idea environment for cell proliferation (Abukawa et al., 2006). In 
addition, mineralized tissue formation was also observed following osteoblast penetration into 
PCL scaffolds (Yoshimoto et al., 2003). PCL containing gentamicin, bovine serum albumin, 
insulin, nerve growth factor and so on have been reported, providing evidence that such 
molecules can be encapsulated by PCL alone and once released have activity in vivo (Sinha et al., 
2004).  
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3.3 Fabrication of PCL biomaterials 
The fabrication of PCL and PCL composites depends on the derived applications. Generally, PCL 
has to be dissolved or melted before further processing. Single and double emulsions with oil in 
water (o/w) and water in oil in water (w/o/w) systems are commonly used to form PCL 
microspheres and nanospheres. Polymer emulsification combined with solvent evaporation can 
be utilized for drug encapsulation within hydrophobic polymers. The emulsification and 
stabilization agents also affect the resultant products of PCL and copolymers (Perez et al., 2000; 
Chen et al., 2000).   
 
Hybrid coating by spray drying or solution immersion can be employed to combine non-organic 
substances with PCL particles and scaffolds. Non organic layers, like HA, can be loaded onto the 
PCL surface and formed a uniform coating to enhance the biocompatibility and hydrophilicity of 
polymers (Yang et al., 2008; Kim et al., 2004
2
). 
 
Porous PCL scaffolds have been made by electrospinning, which enables fibre synthesis on the 
nanoscale, providing space for drug coating and room for cell proliferation to occur.  Electrostatic 
fibre spinning allows ejection of PCL solution toward a grounded collector via a fluid jet at a 
constant flow rate and a high voltage. After that, a non-woven fabric will be cut at the required 
size and then sterilized before further drug or cell loading process (Yoshimoto et al., 2003).  
 
Porous fabric-like PCL scaffolds can also be easily produced by hot-melt homogenization 
followed by precipitation casting (Oh et al., 2007). Melted mixture blending is also a fast and of 
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relatively lower cost which enables production of polymer blends without considerable 
degradation and trans-reaction from chemicals (Antunes et al., 2005). A polymerization reactor 
undertakes proper catalyzed ring opening process and formulation of copolymers; the catalyst 
temperature, duration dimer or trimer catalyst ratio are controllable (Ural et al., 2000). Moreover, 
controlling the 3D structures and pore sizes of tissue replacements propose further approaches of 
scientists (Luciani et al., 2008).   
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Chapter 4 Fundamentals of magnetism and magnetite nanoparticles 
4.1 Magnetism 
Magnetism is a subject, which has been studied for more than thousand years; when a selection of 
ores was found to be ‘attractive’ or ‘magnetic’.  In Europe, iron or Lodestone was later used for 
navigational purposes in a compass.  The first mention of a magnetic device used for establishing 
direction can be found in a Chinese manuscript dated about 1040. The term magnetism describes 
a range of materials but can be diamagnetic, paramagnetic, ferromagnetic and antimagnetic 
(Getzlaff, 2008).  
The symbol of a magnetic field can be referred to either B or H, which are different in both unit 
and definition. The B field is also defined as the magnetic induction or flux density, and the unit 
is Tesla (T) in the SI system and gauss (G) in the CGS system, where one T is equal to 10,000 G. 
The field induced by either pole (south and north poles) of a bar magnet or a magnetic material 
and therefore occurs an internal magnetic field.  The H field, which is also defined as the field 
strength and the unit is ampere per meter (A m
-1
) in the SI system and is oersted (Oe) in the CGS 
system. The B field and the H field is in a linear relationship and in accordance with Equation 4-1, 
where µ is the magnetic permeability of the materials (Chen, 1986; Crowell, 1998). 
 
                                                                                          
 
Figure 4.1 shows the magnetic field pattern around a bar magnet, which is created by the 
superposition of the dipole fields of individual iron particles. The field looks like a big dipole 
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especially farther away from the magnet and bears some resemblance to the magnet’s rectangular 
shape in the area closest to the magnet (Crowell, 2008).  
 
 
Figure 4.1 A typical magnetic field represented by iron filings around a bar 
magnet (Crowell, 2008). 
 
The biggest natural magnetic field is the earth. Permanent magnets can oscillate about a vertical 
axis through their centre, and always turn and come to rest in the same approximately N-S 
direction at a given point on the earth’s surface. One end is called an N-seeking or N pole of the 
magnet and the other end is S pole (Duffin, 1990). There are several types of equipment that can 
supply measurements of magnetism and alternating magnetic fields, such as a Superconducting 
Quantum Interference Device (SQUID) (Lee et al., 2005), a Vibration Sample Magnetometer 
(VSM) (Asmatulu et al., 2005) and Physical Property Measurement System (PPMS) (Lee et al., 
2006).  
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Figure 4.2 Magnetization curves for dia-, para-, superpara- and ferromagnetic 
materials showing the shape and approximate relative magnitude of the 
magnetisation (Heeboll-Nielsen, 2002). 
 
Different magnetic effects can be observed when magnetisms like paramagnetism, diamagnetism 
and ferromagnetism, in matter are formed. Figure 4.2 shows the shape of magnetization curves 
for the different types of magnetism (Heeboll-Nielsen, 2002). The magnetization will saturate 
when in high values of H, which is described as Bsat; and Br is the remnant magnetization, the 
value is the magnetic field of the ferromagnetic materials after removal of external field. The 
coercivity (Hc) is the point at which the B-field is zero. There are only few substances are 
ferromagnetic, for example iron; and some iron alloys and ceramics can be found this kind of 
properties (Hatch and Stelter, 2001). 
Hc
Br
H
B
Bsat
Ferromagnetic
Superparamagnetic
Paramagnetic
Diamagnetic
BBBBBB
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4.1.1  Paramagnetism and Diamagnetism 
If materials contain magnetic moments which can be aligned in an external magnetic field and 
will amplify the field, then such substances have the property of paramagnetism. In contrast to 
ferromagnetic materials (ferromagnetism), there is no permanent magnetization remaining in 
paramagnetic materials when they are removed from the magnetic field. The characteristic of 
paramagnetism can be understood by postulating permanent atomic magnetic moments, which 
can be re-oriented in an external field. These moments can be either due to orbiting electrons or 
due to atomic nuclei. The torque applied by an external magnetic field on these moments will 
tend to fix them parallel to the field, which then reinforces it (Chen, 1986). 
 
Living things mostly consist of diamagnetic molecules. Nearly all organic substances, some 
metals like Hg, and superconductors below the critical temperatures are all diamagnetic. An 
external magnetic field induces magnetic dipoles that are oriented antiparallel with respect to the 
exciting field due to Lenz’s rule (magnetic field is produced in a induced current and the 
magnetism is parallel to the electromotive force). Therefore, the susceptibility, χ, of 
diamagnetism is negative, as shown in Equation 4-2; while that of paramagnetism is 
characterized by χpara > 0 (Getzlaff, 2008; Simon and Geim, 2000). 
 
                                                 Equation 4-2 
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4.1.2 Ferromagnetism 
Particles which have unpaired electron spins align them spontaneously so that the material can 
show magnetizations without being in a magnetic field; such particles are called ferromagnetic. 
Ferromagnetism is a so-called cooperative phenomenon, where single atoms cannot exhibit 
ferromagnetism, but the ferromagnetic properties arise when some of the atoms are bound 
together in solid form. Ferromagnetic particles exhibit permanent magnetization when they are 
removed from magnetic fields. If the field is reversed, ferromagnetic material will initially resist 
the field change, however most domains will eventually switch their magnetization vectors and 
come to the same inverse magnetization (Elliott, 1998).  
 
4.2 Fundamentals of magnetite nanoparticles 
4.2.1 Preparation of nanomagnetite 
Nanomagnetite has been intensively used as fundamental scientific material and for many 
technological applications (Lee et al., 2005); due to a variety of properties include magnetism, 
catalytic, conduction and biological acceptance (Matsura et al., 2004). Accepted applications of 
magnetite nanoparticles are for example: magnetic storage media (Terris and Thomson, 2005), 
Ferro fluids (Sahoo et al., 2005), magnetic resonance imaging (MRI) (Cunningham et al., 2005), 
magnetically guided drug delivery (Dobson, 2006), magnetic bio-separation (Safarik and 
Safarikova, 2004), medical diagnosis (Mornet et al., 2004) and cancer therapy (Zhang et al., 
2002). 
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Colloidal suspensions containing ultra-fine ferro- or ferromagnetic particles are known as 
magnetic fluids, or normally as Ferro fluids (Odenbach, 1993), (Scholten, 1983). In 1965, Papell 
from NASA, developed magnetite nanoparticles for aerospace technology. Nanomagnetite was 
produced by grinding micron sized material for around 1,000 hours (Papell, 1965); this elaborate 
procedure is costly and time consuming. Then, Shimoiizaka produced magnetic fluid via 
chemical co-precipitation, in 1966; nanomagnetite was acquired from the reaction of alkaline and 
a liquid combining ferric and ferrous ion (Shimoiizaka, 1966). In 1972, Khalafalla and Reimers 
achieved an improvement to the process by removing the complex process of absorbing 
surfactant on the surface of nanomagnetite particles; instead, the magnetic fluid was produced by 
co-precipitation and directly introduced into the mixture with surfactant. This method was been 
named as the peptization technique (Khalafalla and Reimers, 1980).  
 
The preparation processes of nanomagnetite have been improved to attain particles with required 
shapes, sizes and magnetism. The production methods of magnetite nanoparticles can be 
separated generally into two approaches, physical and chemical methods. 
 
Physical method  
For many applications, nanoparticles produced from the gas phase are of interest due to their 
physical properties. One of the major methods is to evaporate particulate materials in a tube 
furnace containing ultra-pure nitrogen. Homogeneous nucleation of the vapour takes place during 
the cooling process downstream of the furnace. Particles then grow during homogeneous 
condensation and proceed with the coagulation of primary particles. The coagulation leads to 
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agglomerates that are poly-disperse in the aerosol. The aerosol is charged by a UV charger. The 
particles are then selected using a differential mobility analyser (DMA). In a second furnace tube, 
the step of reshaping by heating takes place. This is necessary for obtaining spherical 
nanoparticles is desired. The size distributions of the nanoparticles are narrowed by a second 
DMA, the particles are then deposited in an electrostatic precipitator (ESP) (Krinke et al., 2002). 
The other major physical method for magnetic nanoparticles is electron beam deposition. Dediu 
et al., 2007, have grown epitaxial magnetite (Fe3O4) thin film by electron beam ablation on spinel 
substrates. The electron beam method uses a pulsed plasma system for ablation. The deposition 
takes place in a reactive which reduce atmosphere from hematite target. The thin films contain no 
impurities, are homogenous over the entire surfaces, and are ferromagnetic at room temperature 
(Dediu et al., 2007). 
 
Magnetic nanoparticles have long been of interest to science and have been synthesized for their 
size and morphologies. However, nanometre scale obtaining particles by physical routes suffers 
from the inability of poor size and shape controlled such as particles produced by gas phase 
deposition and electron beam lithography (Gupta and Gupta, 2005).   
 
Chemical methods  
The size, composition and even morphology of nanomagnetite particles can be appreciably 
controlled by wet chemical methods, which are simpler, more attractive, and efficient (Gupta and 
Gupta, 2005). Iron oxides, Fe3O4 and Fe2O3, can be synthesized from Fe
3+
 and Fe
2+
 aqueous 
solutions with addition of base (Reimers and Khalafalla, 1972). Synthesized magnetite 
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nanoparticles by co-precipitation of ferric and ferrous ions is undertaken typically in a (Fe
3+
 : 
Fe
2+
) 2 : 1 molar ratio (Gupta and Curtis, 2002).  
 
Co-precipitations of magnetite nanoparticles can be achieved by addition of extra base, for 
example, NaOH, NH4OH, LiOH and KOH; the alkalis have different effects on the saturation 
magnetization of products. NaOH is a good choice because of its reasonable price, easy 
availability and does not lead to unwanted product (such as α-FeOOH) in the precipitate (Chen, 
1993). Jeong and colleagues have reported that selected urea or ammonia can be used for 
controlling size distribution by pH value (Jeong et al., 2006). Passing N2 to keep the process 
oxygen free is vital to the production of nanomagnetite. The aerobic condition can critically 
affect the physical and chemical properties of the nanosized magnetic particles. Bubbling N2 gas 
through the solution limits the oxidation of the magnetite and reduces the particle size (Gupta and 
Curtis, 2004; Kim et al., 2001). According to the thermodynamics of co-precipitation, the pH 
value of Fe3O4 precipitate should be between pH 9 and 14 in an inert atom.  Otherwise, Fe3O4 can 
also be oxidized as Fe(OH)3. The overall reaction may be written as Reaction 4-1, which is under 
an oxygen free environment. Otherwise, Fe3O4 might also be oxidized in oxidizing environment, 
as shown in Reaction 4-2 (Gupta and Gupta, 2005). 
 
                                                         Reaction 4-1 
       
 
 
    
 
 
         (  )                                       Reaction 4-2 
 23 
Surface modifications of magnetite nanoparticles 
Weak intermolecular interactions include hydrogen bonds, coordination bonds in ligands and 
complexes, ionic interactions, dipolar interactions, van der Waals forces, and hydrophobic 
interactions (Hamley, 2003). Magnetite iron oxide nanoparticles have hydrophobic surfaces with 
a large surface area to volume ratio. Consequently as a hydrophobic interaction, these particles 
agglomerate and form large clusters with an increase in overall particle size. The clusters display 
strong dipolar attractions to other particles and exhibit ferromagnetic behaviour (Gupta and Gupt, 
2005; Hamley, 2003). The flocculation properties are increased by a global magnetization caused 
from remnant magnetic particles adherent to each other (Gupta and Gupta, 2005).  
 
Since magnetic attraction exists between particles, additional Van der Waals force result in the 
usual aggregations,  and therefore surface modification for effective stabilization of iron oxide 
nanoparticles is indispensable (Gupta and Gupta, 2005). Moreover, for medical applications, the 
stabilised magnetite nanoparticles should be nontoxic, bio-compatible, injectable and have a 
high-level accumulation in the target tissue organ; thus functionalized nanomagnetite have been 
investigated by some researches (Ito et al., 2005). 
 
Surface modification and functionalization of magnetite nanoparticles are achieved by coating 
materials onto the particle. The nanoparticle coating can be comprised of several materials for 
biomedical applications including organic, inorganic, polymeric and non-polymeric materials; e. 
g. polyethylene glycol (PEG), Dextran, polyvinylpyrrolidone (PVP), fatty acid, polyvinyl alcohol 
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(PVA), polyacrylic acid, polypeptides, phosphorylcholine, chitosan and gelatine (Gupta and 
Gupta, 2005). 
 
Surface stability of magnetite nanoparticles  
Stable suspensions of magnetic nanoparticles in different polar solvents are essential for 
biomedical applications.  Surface stability in organic solvents can occur by some possible binding 
schemes, for example, one or two oxygen atoms supply for ions binding onto the Fe
3+
 surface 
(Sahoo et al., 2001). Lee and Harris attached oleic acid by ozonolysis onto the hydrophobic 
surface of magnetite and made it more lypophilic. The double bonds of the oleic acid were then 
oxidatively cleaved by ozone to form carbonyl and carboxyl groups on the nanoparticles surface.  
The alkene chain in the oleic acid reacts with the ozone to form the primary ozonide. Then the 
azelaic acid and 1-nonanal were formed from the unstable primary ozonide and resulted in 
shortened carbon chains with carboxyl and carbonyl groups. The oleate unit of the oleic acid and 
carboxylate unit of the modifier, betain·HCl, undergo a ligand exchange reaction on the 
magnetite particle surface. Finally, the interfacial ligand exchange of the capping molecules was 
applied to make the hydrophobic particle surface more hydrophilic. The addition of these alkyl 
chains led to miscibility in ethanol, resulting a stable nanoparticle suspension (Lee and Harris, 
2006). 
 
Polymeric coatings on magnetic nanoparticles have numerous of applications. Inorganic particles 
in a cross-linked polymer matrix or network of gel can often inhibit coagulations of particles and 
increase monodispersity (Berry et al., 2003). For drug delivery and exact site targeting 
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applications, internalization of nanoparticles into specific cells is a critical step and is limited by 
three factors: short blood half-life, non-specific targeting and low efficiency of internalization of 
endocytosed ligands grafted on to the particles (Gupta and Curtis, 2002). If nanoparticles 
agglomerate or are covered by adsorbed plasma proteins, the particles are quickly cleared by 
macrophages before reaching the target cells. A possible approach to increase the circulation time 
in the blood stream is to modify the surface by poly-(ethylene glycol) (Zhang et al., 2002). A 
PEG is non-immunogenic, non-antigenic and protein resistant (Zalipsky, 1995). Gupta and Curtis 
increased the blood circulation time of nanoparticles by modify the particles surfaces with 
hydrophilic polymers. The nanoparticles were coated by PEG and were incubated with human 
fibroblast for 24 hours. PEG coated magnetic nanoparticles showed no influence of cell adhesion 
in comparison to a control cell population. In addition, it was been demonstrated that particles 
with PEG-modified surface can cross the cell membrane in non-specific cellular uptake (Gupta 
and Curtis, 2002). 
 
4.2.2 Properties of magnetite nanoparticles 
Iron oxide nanoparticles have been interested in their fundamental properties caused by 
multivalent oxidation states, abundant polymorphism, and the mutual polymorphous changes in 
the nanophase. A narrow size distribution for uniform physical and chemical properties is desired 
for technology and clinical applications (Woo et al., 2004).                                                        
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Magnetism in nanoparticles 
In a magnetic system, the magnetic clusters represent an ensemble of atoms which possess 
varying properties with each additional atom. By contrast, nanoparticles do not show significant 
changes of their magnetic properties if the number of atoms are changed by a few. Assuming soft 
magnetic materials without any anisotropy, a continuous vector field of the magnetization is 
expected. Neglecting any crystalline anisotropy a regular domain pattern can already be present 
only caused by the shape, which is due to the minimization of the stray field energy. The 
disappearance in charges of a magnetization vector field has some conditions: it has to be 
divergence-free, i.e. free of volume charges, oriented parallel to the edges of the nanoparticle and 
to the surface to avoid surface charges, and the magnitude of the magnetization vector must be 
constant (Getzlaff, 2008).   
 
Superparamagnetism is the absence of residual magnetic force between particles upon removal of 
the magnetic field. Nanomagnetite exhibits this property such particles are so small, 
approximately below 15 nm, the cooperative phenomenon of ferromagnetism is no longer 
observed and no permanent magnetization remains after the particles have been subjected to an 
external magnetic field. However, the particles still display quite strong paramagnetic properties 
(hence the name of the phenomenon) with a very great susceptibility. (Sorensen, 1998) The 
superparamagnetism of nanomagnetite particles is useful for the biomedical field in the respect of 
magnetic localization and dispersion of actives. The nanoparticles are conveniently controlled by 
supplying an external magnetic field, Jeong et al reported for a series of nanoparticles diameter 
(Jeong et al., 2006). At room temperature, the aerated 5 nm particles were superparamagnetic 
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without interaction among the particles, whereas the 19 nm particles were ferrimagnetic. The 11 
nm iron oxide nanoparticles were superparamagnetic with some interactions among the particles 
(Woo et al., 2004).  
 
The size and morphology of magnetite nanoparticles 
Each application of nanomagnetite requires different material properties; theses can be thermal, 
chemical, colloidal stability, magnetic characteristics, particle shape and size, and non-toxicity. 
The co-precipitation process showed effects on the magnetic properties by concentration 
variation of shape and particle size. Nedkov et al 2006 studied the influence of an oxidizing 
solution and the time of the Oswalt ripening process on the particles shape and size. According to 
XRD and TEM results, the powders obtained were mono-phase Fe3O4 with different sizes, shapes 
and degrees of crystallinity. The shape passes from spherical through elliptical to cubic when the 
oxidizing quantity increases. Then, when the volume of the oxidation solution increases, the 
particle sizes increase and the shape passes from elliptical to cubic. The rate of spinel 
arrangement increases with rising oxidation solution amounts, but the possibility for spherical 
particles preparing decreases (Nedkov et al., 2006).  
 
Different syntheses of iron oxide nanoparticles, such as aerosol/ vapour (pyrolysis) method, gas 
deposition, bulk solution, sol-gel and micro-emulsion methods, have effects on the properties of 
the particles produced and are shown in Table 4.1 (Chen, 1986). The range of nanomagnetite 
sizes are between 5 to 200 nm. Nanoparticles from the micro-emulsion method have a very 
narrow size distribution, 4-15 nm. In the result of bulk solution method, generally, 
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nanomagnetites have spherical morphology, some with porosity or cubic shapes and large 
aggregates appear. The nanomagnetite from aerosol/vapour and sol-gel methods has similar 
magnetization values, 10-50 emu/g; and the particles from the bulk solution and micro-emulsion 
methods show superparamagnetic behaviour. The magnetite nanoparticles formed by micro-
emulsion method have especially a narrow size distribution, exhibit superparamagnetism and lack 
particle aggregation, however low yield rates and surfactant remove from the final product are 
acuse for concern. Both of the advantages and disadvantages are described below. 
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Table 4.1 Comparison of different features of the iron oxide nanoparticles 
fabricated through different methods (Chen, 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3 Application of nanomagnetite in medicine 
The characters of functional magnetic nanoparticles can be applied to a wide range of fields like 
biomedicine (Pankhurst, 2003) and magnetic separation for wastewater treatment and computer 
storage (Nedkov et al., 2006). This work focuses on the nanomagnetite in medicine applications. 
In medicine and biology, magnetite nanoparticles show much attractive practicability. It can be 
Aerosol/ Vapour 
(pyrolysis) method 
 
about 5-60nm 
with broad 
distribution 
 
Spherical 
 
 
10-50 emu/g 
with desired 
magnetic property 
 
High production 
rate 
 
 
 
 
Large aggregates 
are formed 
Gas deposition 
  method 
 
about 5-50nm 
with narrow 
distribution 
 
Spherical 
 
 
>20 emu/g 
 
 
 
Useful for 
protective 
coating and 
thin film 
deposition 
 
Requires very  
high temperature 
Bulk solution 
method 
 
about 10-50nm 
with broad 
distribution 
 
Spherical 
(large aggregates) 
 
20-50 emu/g with 
superparamagnetic 
behaviour 
 
Large quantities 
can be synthesized 
 
 
 
Uncontrolled 
oxidation of  
magnetite to  
maghemite,  
diamagnetic  
contribution 
Sol-gel 
method   
 
about 20-200nm 
with broad 
distribution 
 
Spherical with 
high porosity 
 
10-40 emu/g with 
paramagnetic 
behaviour 
 
Particles of desired 
shape and length 
can be synthesized, 
hybrid nanoparticles 
 
Product usually 
contains sol-gel 
matrix components 
at their surfaces 
 
 
 
Micro-emulsion 
method 
 
about 4-15nm 
with narrow 
distribution 
 
Cubic or Spherical 
(no aggregation) 
 
 
Superparamagnetic 
behaviour 
 
Uniform properties 
and also size of the 
nanoparticles can 
be modulated 
 
Surfactants are 
difficult to remove, 
only a small  
quantities of iron  
oxide can be 
synthesized 
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Size and size 
distribution 
 
 
Morphology 
 
 
Magnetization 
values 
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Disadvantages 
 
 
 
Synthesis of iron oxide nanoparticles prepared by 
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applied to gene technology, as a drug carrier, and cell or object targeting, gene sieve or cell 
separation and tumour therapy.  
 
As mentioned above, magnetite nanoparticles have controllable sizes ranging from a few 
nanometres up to tens of nanometre. These dimensions are smaller than or comparable to those of 
a cell (10 to 100 ìm), a virus (20 to 450 nm), a protein (5 to 50 nm) or a gene (2 nm wide and 10 
to 100 nm long). Thus nanomagnetite can ‘get close’ to a biological entity of interest. 
Furthermore, they can be coated with biological molecules which them enables to interact with or 
bind to a biological entity. It means that magnetite particles can be applied to ‘tagging’ or 
labelled by providing a controllable absorption. Moreover, the iron oxides nanoparticles are 
magnetic, which means that they obey Coulomb’s law, and can be manipulated by an external 
magnetic field gradient. The possibility of action at a distance, combined with  an intrinsic 
penetrability of magnetic fields in to human tissue provide many applications, such as the 
transport and/or immobilization of magnetic nanoparticles, or magnetically tagged biological 
entities.  
 
As a result, magnetite nanoparticles can be produced for delivering an object, such as an 
anticancer drug, or a cohort of radionuclide atoms, to a targeted region of the body, like a tumour 
or trauma. In addition, the magnetic nanoparticles can be made resonantly responding to a time-
varying magnetic field. This is related to the transfer of energy from the exciting field to the 
nanoparticles. For instance, the particle can generate heat which leads to their use as 
hyperthermia agents; delivering toxic amounts of thermal energy to targeted bodies such as 
tumours; or as chemotherapy and radiotherapy enhancement agents, where more effective 
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malignant cell destruction results from a moderate degree of tissue warming. Many other 
potential applications are made available in biomedicine because of the special physical 
properties of magnetic nanoparticles (Pankhurst, 2003).  
 
Magnetic separation 
Specific molecule isolation and separation are used in a wide range of biosciences and 
biotechnology. Over the years, the attention to magnetic separation techniques has increased. For 
example, protein and peptide isolation of biosciences and biotechnology is usually performed 
using chromatograph, electrophoresis, ultra filtration and precipitation with affinity 
chromatography being one of the most important techniques. However, all of the standard 
column liquid chromatography procedures cannot cope with samples containing particulate 
materials; thus, they are not appropriate techniques to early stage purification or isolation 
processes in which samples within are suspended solids and fouling components. Magnetically 
stabilized fluidized beds or magnetically modified two-phase systems have shown their 
usefulness. The magnetic separation of protein can be performed using a concentrated protein 
concentration instead of large volumes of diluted protein solution by standard a chromatography. 
Generally, magnetic separation is extremely gentle to the target proteins or peptides, even to large 
protein complexes which tend to be broken up by traditional column chromatography techniques 
(Safarik and Safarikova, 2004). Magnetic separation is a two-step process, including tagging or 
labelling of the desired entity with magnetic materials and separation of these tagged entities 
through a fluid-based magnetic isolation device (Zhang and Misra, 2007).  
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Tagging ability of magnetic nanoparticles is made possible via chemical surface modifications. 
Such modifications include biocompatible dextran, PVA. The magnetically labelled materials are 
separated from their native solution by passing the fluid mixture via a region where a magnetic 
field gradient exists for immobilization by a magnetic force. The force has to overcome the 
hydrophobic drag force acting on the magnetic particles and there is also a buoyancy force 
affecting the motion (Pankhurst et al., 2003). Following an incubation period when the target 
compounds bind to the magnetic particles, the whole magnetic complex is easily and rapidly 
removed from the sample using an appropriate magnetic separator (Safarik and Safarikova, 2004). 
  
Drug delivery  
Another possible application of magnetic nanoparticles is in drug delivery. Magnetically targeted 
drug delivery can control drug aggregation on trauma areas and as higher repair efficiency. It also 
can be used to reduce drug doses, the cost related with drug treatment and potential side effects 
on healthy tissues, liver or kidney (Weissleder et al., 1995; Dobson, 2006).  
 
Ideally, nanomagnetite could bear on their surface or in the bulk surface a pharmaceutical drug 
that could be driven to the target organ and released there. For these applications, the size, charge 
and surface chemistry of magnetic particles are particularly important and are strongly affected 
on both the blood circulation time and biocompatibility (Chouly et al., 1996). Larger particles, 
200nm, are usually sequestered by the spleen because of its mechanical filtration and are 
eventually removed through the phagocyte system, which leads to decreased blood circulation 
times. Whereas, smaller particles of 10nm or less which are rapidly removed through 
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extravasations and renal clearance. The diameters of particles from 10 to 100 nm are ideal for 
intravenous injection and exhibited the most prolonged blood circulation times (Gupta and Gupta, 
2005).   
 
Magnetite nanoparticles have been successfully designed as a novel magnetic targeting drug 
carrier with characteristics of controlled release. In the study, the surface of magnetite 
nanoparticles was functionalized by Fe-S covalent bonds, and cross-linked with a thermo 
sensitive polymer, which was encapsulated with doxorubicin. According to FTIR results, the 
doxorubicin was chemically conjugated to the surface of the functionalized magnetite. The smart 
stimuli-responsive polymer showed abilities of drug delivery and controlled release by operation 
at a lower critical solution temperature (LCST) and pH value. The system has lower drug release 
at conditions below the LCST; at a temperature higher or equal to the LCST the drug release was 
rapid for the initial 5h, followed by a sustained release for a longer duration (Zhang and Misra, 
2007). Morever, some research preceded magnetic drug delivery by utilising external magnetic 
fields through changing fluid speeds, magnetic distance, magnetic saturation and solid contents 
(Asmatulu et al., 2005). 
 
Hyperthermia affects and Heating treatments 
The application of magnetic materials to hyperthermia dates back to 1957 when Gilchrist et al 
heated various tissue samples with 20 to 100 nm size particles of γ -Fe2O3 exposed to a 1.2 MHz 
magnetic field (Gilchrist et al., 1957). Generally, the method includes dispersing magnetic 
particles throughout the target tissue, and then applying an AC magnetic field of sufficient 
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strength and frequency to cause the particles to heat (Pankhurst et al., 2003; Wada et al., 2003). 
Magnetic induction hyperthermia is one of the therapies for cancer treatment; by exposing cancer 
tissues to an alternating magnetic field. The magnetic field is not absorbed by the living tissues 
and can be applied to deep regions in the living body. Heat is generated due to magnetic 
hysteresis loss when magnetic particles are subjected to a variable magnetic field (Gupta and 
Gupta, 2005). 
 
Cancer cells can be destroyed at temperatures higher than 43 °C for 30 min or more, whereas the 
normal cells can survive at higher temperatures. The majority of hyperthermia devices are 
restricted in their utility because of unacceptable coincidental heating of healthy tissue. Magnetic 
particle hyperthermia is appealing because it offers a way to ensure only the intended target tissue 
is heated (Gupta and Gupta, 2005; Gordon et al., 1979). The size of the magnetite crystals should 
be sub-micrometric, so the powders or bulk of these biomaterials have comparable properties. 
These kinds of materials are not only biocompatible, but also bioactive and could be useful for 
bone tumours (Gordon et al., 1979). Iron oxides, magnetite (Fe3O4) and maghemite (γ -Fe2O3) 
are the most studied to date result from the generally appropriate magnetic properties and 
biological compatibility. Particle sizes less than about 10µm are normally considered small 
enough for effectively delivery to the cancer, either via encapsulation in a larger moiety or 
suspension in some sort of carrier fluid (Pankhurst et al., 2003).  
 
Ferrimagnetic particles possess hysteretic properties when exposed to a time-varying magnetic 
field, which gives rise to magnetically induced heating. Measurements of the heat generation 
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from magnetic particles are usually quoted in terms of the specific absorption rate (SAR) in units 
of Wg
−1
. Superparamagnetic materials are capable of generating impressive levels of heating at 
lower fields (Gupta and Gupta, 2005). Two time constants exist during heating the Brownian 
mechanism of relaxation the magnetic moment is locked to the crystal axis and when the 
magnetic moment aligns with the field, the particle rotates as well. A second mechanism exists 
(Néel relaxation) in which the magnetic moment rotates within the crystal (Rosensweig, 2002).  
 
There are several types of heating devices for varying requirements, such as capacitive plate 
applicators, intraluminal applicators, microwave antennas and phased-array heating strategy. The 
heating device of closed-loop feedback control of microwave heating using MRI temperature 
monitoring, is showed in Figure 4. Using a relatively simple one-dimensional dipole antenna 
array, control of both temporal and spatial temperatures and specific absorption rate values is 
possible. Developing this kind of feedback systems for human scale and integrating them with 
clinical MRI scanners, the efficacy of hyperthermia treatment for a number of different cancers 
can be further improved (Behnia et al., 2002). 
 
Interstitial heating using magnetic nanoparticles is feasible in patients with previously irradiated 
and locally recurrent prostate cancer. Using computed tomography (CT), deposits of magnetite 
nanoparticles appear at a mean density of 450 HU and can be visualized in prostate tissue with a 
sensitivity of around 90 %. An alternating magnetic field applicator for use in humans, with 
operating and variable field strengths is shown in Figure 4.3. A fibrotic thermometry unit and a 
computer console with application software for online thermotherapy monitoring are connected 
to the applicator (Johannsen et al., 2007). 
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Figure 4.3 Alternating magnetic field applicator for use in humans (MFH300F, 
Mag-Force Nanotechnologies AG, Berlin) operating at a frequency of 100 kHz 
and a variable field strength (0-18 kA/m) (Johannsen et al., 2007). 
 
Furthermore, two or more round capacitive plate applicators energized with radio frequency 
electric currents are one of the systems used to supply electromagnetic energy to cancer patients 
undergoing hyperthermia. A system with a smaller applicator on the side nearest the tumour can 
more effectively heat the tumour if the applicator can be located near the tumour, and if the path 
between the applicators and the tumour is not too obstructed by bone. Therefore, such a system 
could be more desirable than a large applicator system (Orcutt et al., 1990). 
 
Tissue repair and tissue engineering  
Iron oxide nanoparticles can be used for tissue repair through welding, apposing two tissue 
surfaces then heating the tissues sufficiently to join them, and through soldering, where protein or 
synthetic polymer-coated nanoparticles are placed between two tissue surfaces to enhance joining 
of the tissues (Gupta and Gupta, 2005). Nanoparticles that strongly absorb light corresponding to 
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the output of a laser are also useful for tissue-repairing procedures. This technique can minimize 
tissue damage through using the least harmful wavelengths of light or lower powered light 
sources. Superparamagnetic nanoparticles can couple to stem cells and used to target them at the 
desired position in the body. In addition, various proteins, growth factors, etc., can bind to 
superparamagnetic nanoparticles and be delivered at the damaged tissue, where they would assist 
tissue development. The use of stem cells in the form of cell-based therapies are known to offer 
tremendous potential for disease, treatment and cures for several diseases including diabetes, 
cancer, heart disease, Alzheimer’s and Parkinson’s. Central to this process would be the ability to 
target and activate these stem cells at required sites of injury and repair using magnetic particle 
technology (Bulte et al., 2001). 
 
On the other hand, since magnetic nanoparticles labelled with cells can be manipulated by 
magnets. A novel tissue engineering methodology using magnetic force and functionalized 
magnetic nanoparticles has been proposed by A. Ito and colleagues; they developed a novel 
methodology to construct 3-D tissue analogues of in vivo tissues using magnetic nanoparticles 
and a magnetic force. These results suggest that magnetic force-based technology is a promising 
approach for tissue engineering (Ito, 2004). 
 
Magnetic resonance imaging 
There has been an increase in interest regarding the use of magnetic nanoparticles as contrast 
agents in magnetic resonance imaging (MRI). The magnetic field distribution of the magnetic 
nanoparticles can be detected using the magneto impedance sensor. Furthermore, its distribution 
 38 
indicated that the magnetic nanoparticles were localized only in the tumour. When these 
apparatuses are available for clinical use, the diagnosis of metastatic cancer with high sensitivity 
will be possible (Ito et al., 2005). 
 
Moreover, magnetic nanoparticles have been used to detect apoptosis by MRI. The MRI 
technique can detect apoptosis at an early stage in the process which has advantages over other 
methods like magnetic resonance spectroscopy (MRS) and radionuclide techniques (Zhao et al., 
2001). Biocompatible magnetic particles have been hypothesized to derivatized with similar 
sequences and that entire particles can be efficiently ferried into haematopoietic and neural 
progenitor cells in quantities up to 10-30 pg of Suerparamagnetic iron per cells (Lewin et al., 
2000). In other research, iron incorporation did not affect the cell viability, differentiation, or 
proliferation of CD34+ cells. Following intravenous injection into immune deficient mice, 4% of 
magnetically CD34+ cells homed to bone marrow per gram of tissue, and single cells could be 
detected by MRI in tissue samples. In addition, magnetically labelled cells that had hoped to the 
bone marrow could be recovered by magnetic separation columns (Gupta and Gupta, 2005). 
Evidence has been presented that the expression can be visualized noninvasively by MRI in vivo. 
The transgenic was used conjugated human holo-transferrin with iron oxide nanoparticles and 
showed an increase in receptor levels at the cell surface that can cause considerable changes in 
MRI signals (Weissleder et al., 2000). 
 
In magnetic resonance imaging, superparamagnetic particles made of iron oxide can be used as 
contrast agents, and strongly influence the relaxation times which depending strongly on the size 
and coating of the particles (Sorensen, 1998). In comparison to paramagnetic ions, super-
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paramagnetic iron oxide particles have higher molar relaxivities, and offer advantages at low 
concentrations as being blood pool and tissue-specific agents (Saini et al., 1987). The 
superparamagnetic iron oxide nanoparticles (SPION) label is highly sensitive to magnetic 
resonance detection and is also relatively non-toxic. SPION has been approved for clinical use as 
a blood pool agent for MRI (Nunn et al., 1996). Because SPION has a large surface area to 
volume ratio, the magnetic nanoparticles tended to agglomerate and adsorb plasma proteins 
(Storm et al., 1995). 
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Chapter 5 Applications of this work 
The main aim of this thesis was to produce MP microspheres which could soften by the locally 
generated heat from the encapsulated magnetite nanoparticles. The work presented in this thesis 
has two fields of application followed by the production of MP particles, as a heating source to 
soften MP particles and as a drug release device. 
 
5.1. The use of magnetite in heating PCL 
To induce the heat generated by the magnetite nanoparticles, an alternating magnetic field is 
required. Scientists are still keen on the achievement of an alternating magnetic field with high 
efficiency of heating and varied power supply for different magnetic particles (Mornet et al, 
2004). A modified magnetic field is employed to demonstrate the heat generation of magnetite 
and therefore softening of MP particles. 
 
5.2. Drug release from MP microspheres 
Magnetite nanoparticles have applications in drug delivery and cell targeting. Nanomagnetite 
within PCL microspheres can also be used for localised delivery of drugs to bone (Yang et al, 
2006). The drug release from the resultant particles and the drug efficacy after release are 
evaluated in the final chapter.   
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Chapter 6 Physiochemical characterisations and statistical analysis 
For a newly synthesised material, it is important to determine physical and chemical properties to 
see that it is suitable for a particular application.  Nanoparticles and microparticles are the two 
major products in this thesis and characterisation has focussed on determining their properties. 
The techniques below are standard methods for particle analysis of magnetite and PCL. There are 
three major parts of this chapter: size distribution, morphology and physiochemical 
characterizations. In addition, further specific methods are described in each results chapter.   
 
6.1 Particle size distribution  
Particle size distributions are conventionally measured by dynamic techniques. The motions of 
molecules in solution are determined by fluctuation and detected by an intensity autocorrelation 
function built into the equipment. (Placidi and Cannistraro, 1998). In light scattering systems, a 
laser strikes the particle and is diffracted.  The nature of diffraction can then be used to determine 
particle size (Eshel et al., 2004). Electron microscopy also be employed to determine particles 
size distribution.  
 
6.1.1 Nanoparticles 
The magnetite nanoparticles were filtered through a 0.45 mm filter; to avoid deviations given by 
impurities. Subsequently, the magnetite nanoparticles were dispersed in distilled water in a 
cuvette and a High-Performance Particle Sizer (HPPS) (HPPS, Malvern Ltd., UK) was used to 
determine the particle size distribution (PSD). The size distribution can be depicted as signal 
intensity, volume/mass moment or number of objects. In the HPPS system, the mean value of 
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particle size shown as Z-average, which is the cumulative mean of the signal intensity.  The Z-
average, however, is only comparable if the sample is monomodal, spherical and monodisperse 
(Rawle, Malvern Instrument Ltd.). Therefore, the other two values, volume and number given 
from HPPS results, can be used to observe polydisperse samples or discuss the particles 
dispersion behaviour. 
 
6.1.2 Microparticles 
The particle size of the microspheres was determined by used laser diffraction (Mastersizer 2000, 
Malvern Ltd., UK). The resultant PCL microspheres were dispersed into distilled water and were 
consequently loaded into the water flow through the laser diffraction area. The statistics from 
Mastersizer give three percentile readings, d0.1, d0.5 and d0.9. The values of d0.1 and the d0.9 are the 
size of particles, and indicate 10% and 90% of the sample below d0.1 and the d0.9 respectively. The 
d0.5 value is that at which 50% of the sample is smaller and 50% is larger. The width of the size 
distribution is given by the measurement of the value of span, which is calculated from d0.1, d0.5 
and d0.9 (Malvern Ltd., UK). 
 
6.1.3 Statistical analysis 
The statistical analysis was determined using a one-way analysis of variance, ANOVA, and 
paired comparison by Tukey multiple range test (Brightstat.com). 
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6.2 Morphological observation 
The morphologies of the nanoparticles and microparticles were captured by different types of 
electron microscope.  
 
6.2.1 Transmission electron microscopy (TEM)  
Transmission Electron Microscopy (TEM) is useful to determine particles morphologies on the 
nano-scale, and allows size determination from the resulting 2D micrographs. Concentrations of 
magnetite nanoparticles were diluted by toluene and ultrasonicated for 2 minutes, then followed 
by loading carefully onto a 400-mesh carbon film (Agar Scientific Ltd., UK) and left to air-dry 
for approximately one to two minutes before TEM (Philips TECHNAI F20, The Netherland) 
analysis (Woo et al, 2004).  
 
Encapsulated microspheres were sectioned and then images were captured using TEM (JEOL 
1200EX, JEOL Ltd., UK).  Samples were first embedded in white resin and sealed in gelatine 
prior to sectioning.  The resulting blocks were trimmed and sections cut using an ultramicrotome 
prior to observation by TEM (LR White, Agar Scientific Ltd., UK). 
 
6.2.2 Environmental Scanning Electron Microscopy (ESEM) 
Some particles were easily dehydrated in the vacuum system of SEM and other particles are 
sensitive to the electron bombardment of TEM.  Lower pressure SEM has been developed 
especially for biological samples. In the ESEM system, the morphology and analysis of specimen 
can be investigated under a moist environment because the water can be condensed as well as 
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vaporised from the sample in a controlled manner (H. M. Ortner, 1999). Furthermore, ESEM can 
be applied to both wet and dry samples.  
  
A conducting layer on the surface of specimen is required in SEM system, which allows the 
electron beam to be conducted through the specimen.  Gold film was deposited onto the surfaces 
of PCL and MP particles with 8 to 10 mm in thickness.  Then, the images were acquired using the 
ESEM (Philips XL30 ESEM-FEG, USA) under a spot size 4 and 10 mm and working distance 
and accelerating voltages of 10 or 15 kV. Particles were mounted onto aluminium stubs with a 
carbon tape before sputter coating. 
 
6.3 Physiochemical Characterizations 
6.3.1 Superconducting Quantum Interference Devices (SQUID) 
The magnetometer, SQUID (S100, Cryogenic Ltd., UK), was using to determine the magnetic 
saturation of magnetite nanoparticles and MP microspheres. The SQUID magnetometer is a high 
sensitivity piece of equipment capable of measurement as low as 10
-7
 emu to 10
-10
 Am
2
 and the 
measurements can be made over a range of fields and temperatures (Cullity and Graham, 2009). 
The Josephson junction is the key element of SQUID, which is built using a thin insulating layer 
between two superconductors and is connected to a superconducting loop for measuring the 
impedance.  The change of the flux applied to the loop will cause the impedance of the loop, and 
the impedance becomes a periodic function of the magnetic flux threading the SQUID due to the 
phase difference across the junction.  Therefore, a bias current of modulation signal is used with a 
detector to measure the impedance and linear relationship of the voltage and flux. Therefore, the 
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sensitive about voltage-to-flux can be used to undertake flaw characterization, magnetic property 
analysis of materials and evaluate corrosion (Wikswo, 1995; Jenks et al, 1996). 
 
6.3.2 X-ray diffraction (XRD) 
Structural phase identification was measured by X-ray diffraction (XRD) (D8, Bruker LTD., UK). 
The XRD peak under the Scherrer approximation was calculated for coherently diffracted domain 
size (dxrd). The peak assumes the small crystallite size to be the cause of line broadening (Thapa 
et al., 2004). Research has shown a good agreement of particle size between XRD and 
magnetization measurements, and it indicated that XRD technique can be used to estimate 
saturation magnetization values (Mahadevan et al., 2007).  
 
6.3.3 X-ray computed microtomography (Micro-CT) 
Micro-CT has recently been employed to undertake 2D and 3D analysis of bone scaffolds. In a 
Micro-CT system, a sample is placed onto a rotating mount and irradiations from X-ray source 
and sample are captured by a detector. The X-ray path captured by the detector is calculated and 
the attenuation coefficients are derived to convert threshold values, which allow more correlate 
information collecting, such as 2-D and 3-D model, porosity and density of the sample (Ho and 
Hutmacher, 2006). 
  
6.3.4 Differential scanning calorimeter (DSC) 
The thermal transitions of PCL were measured by a differential scanning calorimeter (DSC) 
(Pyris 1 DSC, PerkinElmer, UK). For DSC measurements, a sample is sealed in an aluminium 
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pan, and the temperature and heat flow of sample are monitored during heating and cooling 
processes. One sealed empty aluminium pan is used as reference for computing calculation. The 
heating rate used in this thesis is 10°C per minute and argon gas was chosen as carrying gas to 
provide a reducible and dry atmosphere (Hohne et al., 2003).  
 
6.3.5 Thermogravimetric Analysis (TGA) 
Thermogravimetric Analysis (TGA) (TG209 F1 Iris® , NETZSCH-Geraetebau GmbH, Germany) 
was used to measure mass change and the quantity of magnetite encapsulated into PCL. The mass 
variation is observed under a heating process with a controlled atmosphere in an enclosed system 
(Brown, 2001). For the TGA measurements in this thesis, the pressure of air and nitrogen was 
fixed at 25 mmHg, and the heating was set from 25 °C to 800 °C (50 °C/min) with an end-point 
at 820 °C. 
 
6.3.6 Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier Transform Infrared Spectroscopy (FTIR) (Nicolet 380 FT-IR, Thermo Scientific, USA) 
was used to evaluate the functional groups present in the samples by collected spectra measured 
by the temporal coherence of a radiative source. The Fe-O and O-H peaks were used as indicators 
of magnetite particles (Arruebo, 2006) 
 
6.3.7 Energy dispersive Spectrometer (EDS) 
An ESEM fitted with an energy dispersive spectrometer (EDS) (INCA 300 EDS, Oxford 
Instruments, UK) was employed to undertake compositional analysis while evaluating MP 
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morphology.  An X-ray detector is used for detecting and converting X-rays into electronic 
signals which will be measured by a pulse processor to determine the energy of the detected X-
ray.  Then, the data analyzer carries on the peaks identification and quantitative analysis (Oxford 
Instruments, 2005).  
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Chapter 7 The influence of process conditions on the physicochemical 
properties of magnetite nanoparticles   
7.1 Introduction 
The formulation of nano-scale magnetite has received a large amount of attention, due to its 
attractive properties to the biomedical field. Several reports have focused on producing 
functionalised and nano-scale magnetite by chemical and surface modification methods (Lin et al, 
2007). The chemical modification of magnetite might be harmful to bioactive materials because 
of the extra acid or other chemical agents that are used; and this might limit the range of 
magnetite applications in vivo.  There is, however, significant scope for controlling size 
distributions by changing mixing conditions.  Despite this, there is relatively little reported on 
this in the literature.  In this chapter, to achieve a simple production method of control size, 
magnetite nanoparticles were formulated by systematically changing mixing conditions. 
  
This section reports the influences of varying stirring rates, dropping rates and the concentration 
of hydrolysis agent on particle size distribution of magnetite nanoparticles.  The resulting 
particles were characterised with respect to their morphology, electric charge, and magnetic 
saturation, crystalline and thermal stability. 
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7.2 Materials and methods 
Magnetite particles were synthesised by a surfactant-free, oxidative alkaline hydrolysis process. 
The ferric and ferrous chlorides (FeCl3/FeCl2) were added in the molar ratio of 2:1 in the liquid.  
5.2 g of FeCl3 (BDH Chemicals Ltd.) and 2.0 g of FeCl2 (BDH Chemicals Ltd.) were dissolved 
in 25 ml double distilled water containing 850 µl of a controlled concentration (1.5 M or 12 M) 
of HCl (Fisher Scientific).  The reaction medium was stirred gently using a magnetic stirrer. The 
solution was then deoxygenated by bubbling N2 gas for approximately 30 minutes. Following this, 
the solution was added drop-wise into 250 ml of 1.5 M NaOH (Riedel-de Haёn) solution whilst 
stirring with an overhead impeller. The resulting precipitate was washed three times using double 
distilled water and was centrifuged at 3260 ×g for 15 minutes to separate it from the solution.  
Finally, 500 ml of 0.01 M HCl solution was added to the precipitate prior to re-centrifugation at 
3260×g for 15 minutes (Kang et al., 1996). A schematic of the process of magnetite production is 
shown in Figure 7.1:  
 
 
Figure 7. 1 Schematic diagram illustrating the process of magnetite production 
by a surfactant-free hydrolysis method. Step (1) deoxygenated by nitrogen gas, 
(2) drop-wised addition into 1.5 M NaOH under a high-speed mixing, (3) 
washed and centrifuged 3 times, (4) precipitated and suspension drained prior 
to freeze-drying and (5) dried magnetite nanoparticles attracted by the 
attached magnet. 
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To determine the influence of FeCl3/FeCl2 addition and agitation rate on particle size, precipitates 
were formed using different dropping rates and stirring rates, shown in Table 7.1.  Samples A to 
E were intended to investigate the effects of changing the stirring rates. Samples F to M were 
prepared for identifying the effects of dropping rates.  During particle formation, the hydrolysis 
step is the key factor that affects product size and crystallinity.  Sample N and O were used to 
observe the size differences resulting from the acid hydrolysis step.  Finally, these three 
controlled variables were combined and modified to synthesize magnetite nanoparticles of ideal 
size for further work shown as sample P to U. Further details will be illustrated in each section 
below.    
 
Table 7.1 List of magnetite samples for different variables. 
  A  B  C  D  E  F  G  H  I  J  K  L  M  
Stir 
(Np) 
2.4 2.0  1.7 1.5 1.3 ( ----------------------- 1.7 ----------------------- ) 
Drop 
(ml/sec)  
( ------ 0.44 ------ ) 0.48 0.46 0.39 0.36 0.34 0.28 0.20  0.18 
HCl (N)  ( ------- 1.5 ------- ) ( ----------------------- 1.5 ----------------------- ) 
       N  O    P Q R S T U   
Stir 
 (Np)  
   ( 1.7 ) 
 
( ---------------- 1.7 ---------------- ) 
 
  
Drop 
(ml/sec)  
   ( 0.44 )  0.44 0.40 0.36   0.32 0.28 0.24  
HCl (N)      1.5  12    ( ---------------- 12 ---------------- )   
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7.2.1 The influence of stirring rate on particle size distribution 
In order to obtain consistent mixing conditions, the stirring rates were controlled by an overhead 
impeller (Heidolph, type: RZR 1) at various speeds from 1700 rpm to 2100 rpm. The particles 
were produced at five different stirring rates at a constant dropping rate of 0.44 ml/s and 
measured by dynamic light scattering (HPPS). The stirring rates of sample A, B, C, D and E were 
1700, 1800, 1900, 2000 and 2100 rpm, respectively, which are converted  separately to a power 
number, NP, by Formula 7-1 as shown in Table 7.1. In Formula 7-1, P is the power output of the 
machine; ρ is the fluid density, n is the rotation speed and d is the diameter of impeller. NP is a 
dimensionless value indicating the power drawn by the impeller (Green and Perry, 2007) 
 
       
     (    )    ⁄ (    ⁄ )    (   )    ( )⁄                        7-1 
 
7.2.2 The influence of dropping rate on particle size distribution 
In this production method, a black precipitate formed when the iron solution was added drop-
wise into the alkaline solution with vigorous stirring.  The colour change of the solution indicated 
the formation of magnetite.  In order to determine the effects of addition rate, the dropping rates 
were controlled by a peristaltic pump (Watson-Marlow, type 101U/R) to the values between 0.18 
ml/sec and 0.48 ml/sec, as shown in Table 7.1. 
 
7.2.3 The influence of acid concentration on particle size distribution 
In a precipitation reaction, the nucleation and growth steps are critical in determining the size of 
the particles. The initial dissolution of the iron complex in acidic medium frees both Fe
2+
 and 
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Fe
3+
 for further reactions. The concentration of HCl plays an important role in this step (Jolivet et 
al., 1992, Jeong et al., 2006).  Therefore, to investigate the effects of HCl dissolution, the iron 
complex was formed in two different HCl concentrations, 1.5 M and 12 M. 
 
7.3 Results and Discussion 
Magnetite nanoparticles were synthesized by combination of Fe
2+
 and Fe
3+
 solution in various 
mixing conditions.  Then various devices were used for characterization and measurement of the 
particles. In this section, the influence of mixing conditions and HCl concentration on particle 
morphology, zeta potential, magnetism and composition are reported.  
  
7.3.1 The influence of stirring rate on particle size distribution  
Dynamic light scattering was employed to measure the magnetite nanoparticles, all reported 
values are the mean of five repeats.  Figure 7.2 shows the size distribution of hydrodynamic 
diameter by number percentage for magnetite. To form sample A, B, C, D and E, iron aqueous 
solutions were dropped into NaOH at a constant speed with five different NP. The results show 
that magnetite particles distributed mainly in between 98 nm and 167 nm under the initial 1.5 N 
HCl hydrolysis process. Over all, the five curves of particle size distributions presented by the 
number percentage, display a relatively narrow range; and show no significant difference in the 
size range.  
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Figure 7.2 Particle size distributions of magnetite obtained at different NP. 
 
At different stirring rates, the fluid behaviour can be quantified by their relative power numbers, 
NP; and Reynolds numbers, ReI (I indicates mixing by impeller). Table 7.2, presents the mixing 
conditions and the resultant particle sizes of the five specimens. The NP of sample A to E are 
from Table 7.1, Reynolds number (ReI) and power (P) of the mixing conditions were calculated 
by Formulas 7-1 and 7-2 separately; and the mean size of particle distributions are shown in both 
intensity and number percentages. Formula 7-1 has been described in detail in section 7-2.1. In 
Formula 7-2, D is the diameter of impeller, N is the rotation speed, ρ means the liquid density and 
µ is the liquid viscosity. The NP of these magnetite fluids were between 1.3 and 2.4; and their ReI 
were in the range of 6.9×10
4
 to 8.5×10
4
.  
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Typically, the fluid is in a fully turbulent condition throughout the tank when the ReI > 10
4
. 
Otherwise, there is a wide transition region between laminar flow and turbulent flow, which 
occurs over the range 10 < ReI < 10
4
. Turbulent flow is a velocity agitation and is the preferred 
flow regime for mixing (Green and Perry, 2007). The results of ReI and power of the stirring 
conditions have no significant variation; and indicates the fluid behaviours under fully turbulent 
flows with the five controlled Np. 
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Table 7.2 Np, ReI, P and particles size at different mixing conditions.  
 
  Stirring rate  
Power 
Number  
 Reynolds 
Number  
Power  Particle Size (nm) 
  (rpm) (Np) (ReI) (W) Intensity PSD Number PSD 
A 1700 2.4  6.9 x 104  18.0   527.0 ± 28.4  140.0 ± 39.2 
B 1800 2.0  7.3 x 104  18.0  306.0 ± 3.4  167.0 ± 6.0 
C 1900 1.7 7.7 x 104  18.0  328.0 ± 5.2    97.8 ± 33.7 
D 2000 1.5  8.1 x 104  18.0  297.0 ± 3.4   123.0 ± 51.1 
E 2100 1.3  8.5 x 104  18.0  312.0 ± 3.3   144.0 ± 27.7 
 
 
Size distributions of magnetite sample A to E are presented in Table 7.2. The mean particle size 
of sample A to E is varied from 297 nm to 527 nm. Particle size analysis can be demonstrated by 
different mathematical terms, which are fully explained in section 6.1.1 (Rawle). The particle size 
shown in the last columns is the mean value of particle size distribution (PSD) basis in number 
statistics and which is displayed as number PSD. The number PSD of sample A to E is in the 
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range of 80 % to 100 %, which means 80 % to 100 % of particles in the specimen are in the size 
value given by the number PSD. The number PSD is used to compare the value of intensity PSD 
and discuss the particle size distributions. Particle size values for sample A, B, C, D, and E were 
smaller when calculated by number PSD than when calculated by intensity PSD. The particle size 
calculated by number PSD were between 98 nm and 144 nm.  Overall, the mean values of 
intensity PSD were almost 2 to 3 times of the mean values of number PSD (P < 0.001); it 
indicates a broad range of particle size dispersion. The polydispersion can be observed from the 
minor peaks of sample A and C. The other reasons for the differences between the two 
mathematic schemes will be discussed in following sections.  
 
7.3.2 The influence of dropping rate on particle size distribution 
The nano-magnetite particles were synthesised at different dropping rates with a 1.5 M HCl 
solution and with mixing at 2.4 NP.  Samples F to I and sample J to M are shown in Figure 7.3 (a) 
and (b), respectively. Dropping rate had a more significant on particle size distribution as shown 
in Figure 7.4. The particle size varied from approximately 100 to over 1000 nm; sample G had 
the smallest particle size of 92 nm and 330 nm in the number PSD and the intensity PSD 
separately; sample M has biggest size of 1225 nm and 2520 nm in the number PSD and intensity 
PSD separately. There were 90 to 100% of particles in the size range of the number PSD results 
of sample F to M. Figure 7.4 indicates a trend of small size fluctuation from changing the 
dropping rate between 0.34 ml/sec and 0.46 ml/sec (marked by a dashed line), and the same trend 
exists in both intensity PSD and the number PSD results. Larger particles sizes are seen in the 
dropping rate over 0.48 ml/sec. and less than 0.28 ml/sec. For samples F to M, the polydispersion 
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was also showed by the appearance of some minor peaks. In addition, the great differences 
between the intensity PSD and the number PSD values also refer to the wide range of dispersion 
(P < 0.001).   
 
During the precipitation method, small amounts of iron liquid drop into bulk alkaline under 
vigorous mixing. The addition of the iron solution of Fe
2+
 and Fe
3+
 into alkaline under high-speed 
stirring is the key step for the production of magnetite. The particle size distributions show that 
dropping rates have a stronger influence on particle size than stirring speed.  Observations 
suggest that the addition of the iron solution into the base by a peristaltic pump cause adjacent 
drops to be fused together when the pump was set at high speed, and the slower dropping speed 
produced a bigger drop size at the tip of the pipe. Therefore, bigger particles were produced in 
both high and low speeds of the dropping; this trend can be seen in Figure 7.4. The dropping rates 
can be controlled by manipulating the conditions such as the efficiency of the pump and the 
diameter of the pipe used.  These factors can be changed and influenced particles size greatly. 
Alternatively, a rapid injection can be carry out in high temperature solution in a controlled 
manner to form smaller particle size (Hyeon, 2002). 
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Figure 7.3 Nano-magnetite particles at different dropping rates presents (a) 
sample F to I. 
 
 
Figure 7.3 Nanomagnetite particles at different dropping rates presents (b) 
sample J-M. 
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Figure 7.4 Mean sizes of magnetite nanoparticles at different dropping rates. 
  
7.3.3 The influence of acid concentration on particle size distribution  
In addition to mixing conditions, pH values play an important role in particle size distribution and 
stability (Tombacz et al., 2006). Magnetite nanoparticles were produced by a chemical method 
with acid solvents.  At high and low acidic conditions, the size of magnetite can be significantly 
altered.  Magnetite production is under 1.5 M and 12 M HCl, with constant mixing rates (dropped 
0.44 ml/sec and stirred 1.7 NP). The majority of particles (over 80 %) of sample N and sample O 
were distributed in the range of 59 nm to 91 nm and 14 nm to 24 nm, respectively, as the result 
obtained from the number PSD and show in Figure 7.5. The sizes of magnetite are smaller under 
a high acid environment and they become larger when the acid concentration is much lower.  
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Figure 7.5 Magnetite nanoparticles distribution under 1.5 M and 12 M HCl by 
number PSD. 
 
From the results obtained by light scattering, the particle size can be calculated by intensity, 
volume and number distribution of the same sample; this results in separate mean sizes. From 
previous work, aggregation and other certain bigger particles may disturb the results of the 
intensity PSD. Therefore, determination of both volume and the number statistics can be more 
accurate for size distribution. In the volume statistics, the minority of large particles may occupy 
higher ratios of the total results than the majority smaller particles. On the other hand, few big 
particles may be ignored in a number based calculation if they are less than 1 % of the total 
amount. The size distribution by the volume PSD is calculated by the mean of particle volume, 
and it will be disturbed by occasional bigger or smaller sized particles. The size distribution by 
the number PSD is calculated by the mean of particles number as mentioned in previous section. 
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Consequently, particle size distribution can be well understood by comparing volume PSD and 
number PSD. The size distribution from the volume PSD and the number PSD are similar as 
shown in Figure 7.6 and Table 7.3. 
 
 
 Figure 7.6 Magnetite nanoparticles distribution under 12 M HCl (a) by 
number PSD, and (b) by volume PSD. 
 
Table 7.3 Size distributions by volume PSD and number PSD of magnetite 
nanoparticles of Figure 7.6. 
 
 Particles size (nm) 
  (volume PSD) (number PSD) 
P 28.32±1.01 21.86±1.22 
Q 28.90±1.64 23.00±2.13 
R 24.92±0.96 19.84±1.40 
S 29.10±3.93 24.00±5.07 
T 27.52±0.87 22.72±1.22 
U 31.60±0.70 26.42±1.41 
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Compared to Figure 7.3, the sizes of magnetite nanoparticles are smaller and the effects of the 
dropping rates change are significantly less as the results shown in Figure 7.6. The particle size 
for the dropping rates (0.18 ml/sec to 0.48 ml/sec) are from 75 nm to over 1000 nm for the lower 
acid concentration in Figure 7.3, and the range of 12 nm to 59 nm for higher acid concentration in 
Figure 7.6.  The magnetite particles were under the same higher acid hydrolysis step during 
formulation; the effects from pH on particles size are stronger than from shear.  In addition, there 
was enough acid for the hydrolysis process, and the particles can be synthesized in consistent size 
and with minimum in size variation, which shows a good agreement with the volume and the 
number distribution data. The magnetite nanoparticles formed by this method are monodisperse.  
 
The size of magnetite nanoparticles can be affected by several factors, for example the relative 
oversaturation of solution, the appropriate hydrolysis condition controlling pH value and ionic 
strength (Tombacz et al., 2006). In the initial step of magnetite production, HCl was added to 
hydrolyse Fe
2+
 and Fe
3+
 salts; and in the final step washing within water and low concentrated 
HCl. In these two processes, the remaining acid has an effect on the pH value of the final 
products.  Furthermore, before measuring the particle size by light scattering, samples have to 
dilute.  The pH value of the dilution plays an important part in the particles dispersion and 
aggregation.  Indeed, Figure 7.6 illustrates that the effects of pH on the size distribution, which 
have a greater influence much than the dropping rates shown in Figure 7.3.  In addition, Nedkov 
reported that the sizes of magnetite particles are bigger when the volume of the oxidizing solution 
(used in the 2nd step for oxidizing Fe
2+
 to Fe
3+
) is increased, and the shape of magnetite passes 
from spherical through elliptical to cubic.  They compared the two most widely quoted co-
precipitation processes, with and without oxidizing solution; the results showed that there are 
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larger grain-size and more crystalline when using oxidizing solution initially and in contrast 
smaller sized and far worse crystallinity in the absents of the oxidizing solutions (Nedkov et al., 
2006). The ratios of magnetite particle sizes in our study are similar to that in Nedkov’s results, 
where the concentrations of oxidizing solution were varied.  From the above research results, 
different regime of co-precipitation methods have been investigated; varying particle size and 
crystallization of magnetite nanoparticles can be put in use depending on different applications.   
 
Another factor influencing the control of the size of the magnetite particles is particle aggregation.  
Nanoparticles have a large surface area and these results in Van der Waals attractions. As the 
aggregates become smaller during the de-aggregation, surface force become more important than 
mass forces and for aggregates smaller than 1 µm, surface force are more than one million times 
larger than mass force (Kendall and Staiton, 2001). The temperature and pH affects de-
aggregation kinetics but do not alter the de-aggregation pattern. Increasing pH value at low 
temperature could speed up the de-aggregation, whilst increasing pH at high temperature slows 
down de-aggregation process (Pacek et al., 2007). Therefore, the sizes of magnetite obtained at 
different acid concentrations show diverseness as indicated Figure 7.5. 
 
In addition, magnetite nanoparticles were synthesized through co-precipitation of Fe
2+
 and Fe
3+
 
aqueous salt solution and the reaction should be carried out in an oxygen free environment 
(Gupta and Gupta, 2005) otherwise it is very easy to synthesize by-products, such as maghemite  
(Fe2O3). The Fe2O3 produced is known to interfere with the light scattering results. Passing 
nitrogen gas is a general method for creating oxygen free environment in the production of 
nanomagnetite; it not only protects critical oxidation of magnetite but also reduces the particles 
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size (Gupta and Curtis, 2004). However, the step of bubbling nitrogen gas through the solution is 
followed by a high speed stirring process for the formation of magnetite nanoparticles. The 
oxygen in the air would bind and break in the reaction with the iron oxides during the high speed 
mixing step and interfere with the results of particle size distributions as indicated in Table 7.2.  
 
7.3.4 Morphology of nanomagnetite 
A TEM image of magnetite is shown in Figure 7.7. Most of the particles are uniform in shape and 
are relatively small (approximately 10 nm), the dark areas indicate some particle aggregation. 
The magnetite particles have to be sprayed onto a copper film in liquid phase before TEM 
observation.  The large surface area of nanoparticles result in the Van der waals attractions as 
mentioned in section 7.2, this is may be the reason of aggregation shown in the TEM image. The 
average hydrodynamic radii from dynamic light scattering tend to be bigger than those 
determined from TEM, because of particle aggregation and the angles of three-dimension 
particles interfering with the signal intensity.  
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Figure 7.7 Image of magnetite nanoparticles observed by TEM. 
 
The aggregation of nanoparticles is one of the main influencing factors of particle size. The 
image from the TEM result illustrates some darker areas of adjacent particles that aggregated and 
affects the results of particle size. As the results shown in Figure 7.2 and Table 7.2, the mean 
particle size of sample A 527 nm, which is obtained from the mean of signal intensity; but the 
major portion of particles exhibited particles size at 140 nm.  
 
Also, some reports have demonstrated relatively smaller particles compared to this study (Hyeon, 
2002; Pacek et al., 2007; Tombacz et al., 2006; Woo et al., 2004; Thapa et al., 2004; Matsura et 
al., 2004; Jeong et al., 2006); they produced the magnetite particles under 10 nm by controlling 
the temperature, surfactants and surface coating. In a study by Hyeon’s group, the final 
precipitate was aged for 30 min at 320 °C and dispersed by a surfactant afterwards. The resulting 
particle size produced were 2 nm in width and 11 nm in length; the length increased from 22 nm 
to 27 nm by an increasing concentration of surfactant (Hyeon, 2002). We approached the similar 
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particle size distributions to their work of approximately 18nm by altering the mixing rates while 
working at room temperature (20 °C to 25 °C) instead of using chemical surfactants and long 
aging time at high temperature. The high temperature slows down de-aggregation process of 
nanoparticles in water suspensions (Pacek et al., 2007), and surfactants are required for 
stabilisation and to prevent the adhesion of colloidal particles. Altering mixing speed by 
controlling the dropping and stirring rates is relatively easy compared to controlling the amount 
of surfactants and considering the effects of temperature on aggregation.  
 
7.3.5 Electric charge of nanomagnetite 
The surface properties of magnetite are sensitive to pH variations, which affect the dispersion and 
coagulation of magnetite nanoparticles. Moreover, the stability of magnetite is also affected by 
pH value. The transformation of magnetite into maghemite was observed in an acidic 
environment (Jolivet and Elisabeth, 1988) (Sun et al., 1998). The electric charge demonstrated by 
Zeta potential can be used to characteristic the surfaces of magnetite nanoparticles. The point 
zero charge (PZC) of magnetite seems to be at pH 7.61 as shown, Table 7.4, and this value falls 
in the range as reported by Tombacz (Tombacz et al., 2006). The Zeta potentials of magnetite 
particles are negative when the environment in below pH 7.61. For all pH values, the relative 
narrow width of the peaks indicates that magnetite nanoparticles possess a narrow range of 
electric charge within the colloid fluid.    
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Table 7.4 Zeta potential results shown for three pH values. 
 
pH value  KCps  Zeta potential  Width  
7.61, 27.6 ℃  306.7 ± 50.1  0 ± 0  0 ± 0  
7.14, 25.8 ℃   5347.0 ± 65.0            -4.1 ± 0.8  6.9 ± 1.6  
6.82, 24.6 ℃       2423.6 ± 34.1          -12.2 ± 2.6  6.4 ± 0.0  
 
 
7.3.6 Crystalline composition of nanomagnetite 
The crystalline composition of the synthesized magnetite nanoparticles were determined using 
XRD (Figure 7.8). The result shows that the crystalline is most close to the Fe3O4 phase and 
indicates a monophase of the nanoparticles. The intensity of the peaks in the five characteristic 
peaks display at 2θ of 30.1, 35.5, 43.2, 57.0 and 62.8 degree, which corresponded to indices of 
220, 311, 400, 511 and 440 respectively of magnetite (Hong et al., 2007). The diffraction patterns 
of maghemite, the most likely side product of magnetite formulation, are absent. Furthermore, the 
crystalline of magnetite is cubic structure indexed by XRD analysis. Superparamagnetism are 
exhibited in small (less than 100 nm) and single domain magnetic particles (Ma et al., 2004); 
therefore, the results of XRD and SQUID present the agreement of that the magnetite 
nanoparticles are of a single domain and exhibit superparamagnetism.  Understanding the 
magnetism and crystalline purity is useful for defining the mechanism of heat generating by 
magnetite particle in chapter 9.   
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Figure 7.8 X-ray diffraction patterns of magnetite nanoparticles. 
 
7.3.7 Magnetic saturation of nanomagnetite 
The magnetic nature of the precipitation was confirmed using a rare earth magnet.  Attaching a 
magnet at one side of the sample container, and the particles were attracted to the side with the 
magnet after a period of 1 hour.  Figure 7.9 illustrates the Ferro-fluid from brown colour to clean 
by magnet attachment. Statistic magnetisation of magnetite nanoparticles were measured by 
superconducting quantum interference device (SQUID) in two experiments: at three steady 
temperatures (5 K, 300 K and 350 K) with varying magnetic field strengths and a steady 
magnetic field with temperatures sweep in the field.  SQUID results shown in Figure 7.10 and 
Figure 7.11, the magnetisation curves are similar for magnetite particles while in 5 K, 300 K and 
350 K measurements. Afterwards, the magnetite was placed in a 1000 Oe magnetic field for 
measurement with changing temperature.  
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Figure 7.9 Magnetization of magnetite nanoparticles by magnet attraction. 
 
The hysteresis curves of Figure 7.10 indicates superparamagnetic behaviour resulting from the 
coercivity and remanence values are not discernible at 5 K ,300 K and 350 K (Woo et al., 2004) 
(Hong et al., 2007). Furthermore, the magnetisation of magnetite nanoparticles decreased after 
heating by 90 K and keeping steady in a low magnetization state after the temperature reaches 
higher than approximately 270 K, shown in Figure 7.11. The decreases of magnetic saturation 
from 5 K to 300 K are less than 2 emu/g. The loss of magnetisation is comparatively low if it is 
taken into the nanoscale (Banert and Peuker, 2006). The magnetite particles produced by the non-
surfactant method have superparamagnetic behaviour.    
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Figure 7.10 Magnetization at three temperatures (5 K, 300 K and 350 K) with 
different magnetic field sweep by SQUID. 
 
 
Figure 7.11 Magnetization in 1000 Oe field strength and different magnetic 
temperature sweep. 
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7.3.8 Thermal stability of nanomagnetite 
Figure 7.12 show the DSC results of magnetite nanoparticles. There were three repeats for DSC 
measurements. According to the endothermic and exothermic curves, there is no obviously heat 
capacity change and phase transition occurring during either heating or cooling between 25 °C 
and 200 °C. This indicates good stability of magnetite nanoparticles.  
 
 
Figure 7.12 Thermal analysis result of magnetite. 
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7.4 Conclusion 
 
Particle size control of magnetite nanoparticles can be accomplished by the co-precipitation 
method with various mixing speeds and acidic values.  Formulation with different dropping rates 
indicated a trend of small size fluctuation from 0.35 ml/sec to 0.46 ml/sec. The pH value of the 
dilutions displayed a key factor of influencing particle size.  A high acid environment enabled de-
aggregation and good dispersion of the resultant magnetite nanoparticles. Both the number and 
the volume data demonstrated similar size distribution of magnetite nanoparticles synthesized 
with 12 M HCl hydrolysis.  The magnetite nanoparticles in this thesis were formed in the room 
temperature without any heating procedures and chemical modification during the formulation, 
achieved great results of size-control, monophased and superparamagnetism at 5 K, 300 K and 
350 K.   
 
The magnetite nanoparticles formed in the identical conditions was engaged to the production of 
MP microspheres and further works. 
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Chapter 8 Formulation and characterization of PCL and MP microspheres 
8.1 Introduction 
Biocompatible polymers have attracted a lot of interest for the production of biomaterials for 
implantation. As one of the most commonly used polyesters, PCL has been widely applied in the 
formation of different types of biomaterials; such as PCL based scaffolds for tissue engineering 
and PCL/hydroxyapatite composite for bone replacement (Ural et al., 2000; Boccaccini et al., 
2010).  The objective of the work reported in this chapter is to synthesize and characterize 
magnetite/PCL (MP) microspheres. In order to obtain ideal formulation conditions, PCL 
microspheres were formulated by emulsion at different speeds, and the size distribution and 
morphology of PCL particles were discussed. Thereafter, MP microspheres were synthesized 
using the magnetite nanoparticles under the identical condition from previous work (chapter 7), 
and the characterisation of MP particles was defined.  
 
The results section reported the influence of changing mixing speed on size distribution of PCL 
microspheres and the physiochemical analysis of PCL and MP spheres. The property 
determinations of the resultant microspheres include morphologies and distribution of magnetite 
from sections.  MP spheres were also characterised with respect to their composition and 
magnetisation and thermal properties. 
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8.2 Material and Method 
Two different types of PCL, CAPA
®
6100 and CAPA
®
2201 (Perstorp, UK Ltd.), were chosen for 
the production of microspheres. Table 8.1 shows the general product description of the two types 
of PCL, the mean molecular weights were 10,000 and 2000. The melting points were 58 °C to 60 
°C and 40 °C to 50 °C, and the viscosities were 9300 mPa.s and 480 mPa.s, respectively. PCL 
CAPA
®
6100, described as PCL6, is a linear polyester with high molecular weight derived from 
the caprolactone monomer. CAPA
@
 2201, known as PCL2, is a standard grade linear polyester 
diol derived from caprolactone monomer terminated by primary hydroxyl groups, and is waxy in 
texture. 
 
Table 8.1 General product description of the PCL used in this thesis. 
PCL MMW Melting Point Viscosity Physical Form 
CAPA@ 
6100 
10,000 58-60 °C 9300 mPa.s, at 100 °C White Solid 
CAPA@ 
2201 
2,000 40-50 °C 480 mPa.s,  at 60 °C 
White Waxy 
Solid 
 
 
8.2.1 Formulation of PCL microspheres 
The microspheres were prepared using an emulsion solvent extraction/evaporation technique 
(Perez et al., 2000).  300 mg of PCL was dissolved in 10 ml of dichloromethane (Sigma-Aldrich) 
during 1-minute of sonication. Subsequently the PCL solution was emulsified into 100 ml of 2 % 
w/v aqueous poly-vinyl alcohol (PVA) (Sigma-Aldrich) solution utilising a high speed blender 
(SILVERSON, machine serial No. V5100), using a high-speed emulsion rate for 3 minutes. The 
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emulsion was then gently agitated by a shaker at 200 rpm and 20 °C with addition of 50ml of 
distilled water for 3 h until the dichloromethane had completely evaporated. The emulsion was 
then centrifuged at 204 ×g for 5 minutes and washed with double distilled water three times 
before freeze drying (Barbato et al., 2001). The formulation of MP particles is roughly the same 
as the production of PCL microsphere. The process of PCL production is shown below, Figure 
8.1. 
 
 
Figure 8.1 Schematic illustrating the formulation of PCL and MP 
microspheres by an emulsion solvent evaporation technique. Step (1) dissolved 
PCL and magnetite mixing by ultra-sonication, (2) added into 2 % PVA 
solution at a high-speed emulsification, (3) agitated and centrifuged, (4) 
precipitated and suspension drained before freeze-drying. 
 
8.2.2 The influence of changing mixing speed on size distribution of PCL  
The influence for PCL addition rate on particle size was determined by forming precipitates at 
different emulsification speeds, 6000, 5000, 4000 and 3000 rpm. To determine the flow 
behaviour during the emulsification process, the mixing speeds were converted to NP and Re, 
respectively (Formula 7-1, 7-2).  
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8.2.3 Formulation of MP microspheres 
The optimum conditions for PCL and magnetite production were selected for preparing MP 
microspheres. The first step was the same as the preparation of PCL (as described in section 
8.2.1); 300 mg of PCL was dissolved in 10 ml dichloromethane (Sigma-Aldrich) under gentle 
agitation.  Different acquired amounts of magnetite particles were added into the PCL solution 
during sonication.  Subsequently, the PCL and magnetite solution was emulsified into 100 ml of 
2 % w/v aqueous poly-vinyl alcohol (PVA) solution utilising a high-speed blender at a high 
blending rate, 6000 rpm, for 3 minutes.  The magnetite and PCL emulsion was gently agitated by 
a shaker at 200 rpm at 20°C with the addition of 50 ml of distilled water for 3 hours until the 
dichloromethane had completely evaporated. After that, the emulsion was centrifuged at 204 ×g 
for 5 minutes and washed with double distilled water three times before freeze drying. 
 
8.3 Results and Discussion 
Magnetite encapsulated PCL was synthesized after the separate production of nanoscale 
magnetite and PCL particles.  Different devices for the characterizations of the particles were 
used. Firstly, particles size distribution of all mixing rates. Then, the particle morphologies and 
compositions were determined. Following the production and characterisations of PCL 
microspheres, MP microspheres were synthesized and were exposed to thermal treatments and 
drug release investigations. 
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8.3.1 The influence of changing mixing speed on size distribution of PCL 
Size-controlled studies are presented for both PCL2 and PCL6. The PCL2 microspheres, included 
samples A, B, C, and D prepared by using a homogenizer at 6000, 5000, 4000 and 3000 rpm 
respectively. Similarly, PCL6 microspheres, included samples E, F, G, and H, which were 
prepared at 6000, 5000, 4000 and 3000 rpm, respectively. The particle distributions of the PCL 
microspheres were determined by using light scattering at room temperature. The particle size 
distributions (PSD) of the PCL samples were obtained by solvent evaporation method shown on 
Figure 8.2 and Figure 8.3. The resultant data was present in volume statistics by the light 
scattering. The results of A to H are from the mass median diameter (d0.5) of particles distribution.  
 
The results in Figure 8.2 indicate that the size distributions of PCL2 fluctuated across the four 
mixing speeds. For PCL2 particles, there is no significant relationship between mixing speeds 
and resultant particle size. PCL2 particles were distributed between 14.7 μm and 55.6 μm (P < 
0.001). As seen in Figure 8.3, particle growth was found to be greater when the mixing speed was 
slower. The PCL6 particle size was slightly lower than PCL2, ranging from 43.6 µm to 4.4 µm 
when the mixing speed rose from 3000 rpm to 6000 rpm. It can be seen that when the mixing rate 
was reduced to 3000rpm, the size range was almost 10 times larger than the smallest sample, E (P 
< 0.001). In addition, the flow behaviours and mixing efficiencies can be seen in NP and Re, in 
Table 8.2. 
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Figure 8.2 PSD of PCL2 microspheres (d0.5) by varying mixing rates. 
 
 
Figure 8.3 PSD of PCL6 microspheres (d0.5) by varying mixing rates. 
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Table 8.2 Particle size distributions of the two types of PCL microspheres at 
different mixing speeds (3000 rpm to 6000 rpm).  
 
Mixing speed  
(rpm) 
6000 5000 4000 3000 
NP 23.6 40.8 79.6 188.7 
Re 71.8×10
4
 59.8×10
4
 47.9×10
4
 35.9×10
4
 
 
 
d0.1 d0.5 d0.9 S
*
 d0.1 d0.5 d0.9 S
*
 d0.1 d0.5 d0.9 S
*
 d0.1 d0.5 d0.9 S
*
 
size  
(μm) 
PCL2 7 56 143 2 4 15  73 5 7 30  101 3 4 22  62 3 
PCL6 1 4 74 17 1 6  52 9 3 8  38 4 12 44  184 4 
 
S
*
: Span = (d0.9-d0.1)/d0.5; n=3 
 
In Table 8.2, NP and Re were obtained from Formula 7-1 and 7-2 (Green and Perry, 2007). The 
power number was between 23.6 and 188.7 for this range of mixing. Re values are over 10
4
, 
which is in the range indicating fully turbulent flow as discussed in chapter 7. The NP of the flow 
increased irregularly as the mixing speed decreased from 6000 rpm to 3000 rpm. Notably, the NP 
was higher than doubled when the speed was reduced from 4000 rpm to 3000 rpm. The size 
distributions of PCL2 and PCL6 microspheres were illustrated by d0.1, d0.5 and d0.9, and the width 
of distributions were converted and reported in the values, span. Each value was obtained from 
three repeats of every sample (n =3). The particles sizes of PCL6 have relative smaller particle 
size under high speed mixing (P ≤ 0.3), but increase significantly at lowest speeds, of 3000 rpm. 
The size distributions of PCL2 microspheres did not show a strong relationship with emulsion 
methods, but the smallest size distribution also exhibited at higher speed mixing, 5000 rpm. 
However, the span values varied from 2 to 17 while PCL2 and PCL6 microspheres were formed 
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at the four mixing speeds, which indicated the polydisplersion of the resultant microspheres 
(Malvern Ltd., UK).  
 
As mentioned in chapter 7, NP is the dimensionless value of power drawn by impeller. 
Theoretically, the power generated by the machine is 18W; however, it may be varied by 
different flow conditions, such as viscosity of fluid and mixing speed. Consequently, flow 
behaviour and flow efficiency are indentified by discussion of NP and Re. Form the Formula 7-1, 
the relationship between NP and power is an inverse relationship. According to the resultant size 
distribution of PCL6, NP exhibited effects on particles size. On the other hand, particles size of 
PCL2 did not show significant dependence on the variation of NP. Nevertheless, the smallest 
particles of PCL2 and PCL6 are both displayed when lower NP is using (40.8 and 23.6 
respectively).  
 
The other factor effecting the size distribution of PCL particles is the stabilisers used during PCL 
formulation. A report that the preparation of PCL microparticles with different stabilizers 
indicated that depending on the different stabilizer used, different particle size, particle size 
distribution and morphology of microparticles could be produced. Authors suggested that the use 
of gelatine as a stabilizer for PCL gives a narrow particle size distribution and more uniform 
particles. The hydrogen bond of gelatine balances the hydrophilic/hydrophobic effect in the 
emulsion system. According to their results, which compared the ability of gelatine and PVA to 
act as stabiliser, gelatine is effective at preventing aggregation of the emulsion microdroplets, 
whereas PVA is more hydrophilic and could not effectively protect the emulsion microdroplets 
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from coagulation (Chen et al., 2000).  Therefore, the polydispersion of PCL microspheres could 
be attributed to the using of PVA. 
 
8.3.2 Morphology of PCL microspheres 
The images of two types of PCL made at a NP of 23.6 were captured by ESEM as shown in 
Figure 8.4 and Figure 8.5. In Figure 8.4, a collection of PCL2 particles is present at (a) and (b), 
while (c) is a single particle of PCL2. PCL6 particles shown in Figure 8.5, (a) are collections of 
particles which are zoomed in to the single P6 particle in (b). Both PCL6 and PCL2 are spherical 
in shape and well dispersed. The PCL6 particles are approximately 4 μm in diameter under 23.6 
NP mixing process, which refers to the results in Table 8.3.  
 
On the other hand, images of collections and single PCL2 particles are all much smaller than the 
results from light scattering; they are approximately 4 μm to 10 μm according to the particle sizes 
in Figure 8.4. In Figure 8.4 (b), the micrograph shows the wide dispersion of PCL2 sizes, which 
may explain the results given by light scattering. The data were obtained from volume statistics, a 
larger particle occupied higher volume than a smaller particle; therefore, the resultant sizes tend 
to be bigger than actual particle shown by ESEM. Moreover, some particles did not disperse 
properly and were actually bound to each other as seen in Figure 8.4 (b); this may result from the 
waxy property of PCL2 and lead to increased size values due to the fusion of particles. The other 
factor leading to polydispersity or aggregation is the concentration and viscosity of stabilizer.  
Increasing the PVA concentration resulted in smaller and uniform droplet size and leading to the 
formation of low polydispersity (Sahoo et al., 2002; Zambaux et al., 1998) 
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Figure 8.4 Micrographs of PCL2 microspheres: (a) and (b) are the collection 
of microspheres and (c) is the single domain. 
 
 
Figure 8.5 Micrographs of PCL6 microspheres: (a) is the collection of 
microspheres and (b) is the single domain. 
 
 
Figure 8.6 Micrographs of PCL microspheres at wet condition (a) and 
magnification into (b). 
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Figure 8.7 Micrographs of PCL microspheres crushed by a toothpick on the 
stub (a) and magnification into (b). 
 
PCL particles displayed spherical shapes when in the dry storage condition as previous images 
showed, and PCL were also observed at wet and broken conditions. PCL6 particles were stored in 
distilled water and captured by ESEM as shown in Figure 8.6. Some of the particles showed 
aggregation with nearby PCL, as displayed in Figure 8.6 (a). The surfaces of PCL here are 
smoother than in dry conditions and exhibit a slight swelling from absorbing the surrounding 
moisture in (b).  Technically, the surfaces of PCL particles are hydrophobic and less able to 
interact with water. Sahoo and colleagues reported that the residential PVA may affect the 
physical properties of polymer. In their report, there is an increase of the association between 
residual PVA and nanoparticles when the solvent miscibility with water is relative high. The 
miscibility of dichloromethane in water is relative high compared to other organic solvent in their 
work. Therefore, more PVA might intrude into the polymer phase and result in more miscibility 
with the aqueous phase (Sahoo et al., 2002).  
 
PCL2 encapsulated magnetite (MP2) microspheres were crushed by a toothpick to observe the 
morphology of broken particles. Under ESEM observation, parts of MP2 particles are still intact 
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and spherical as shown in previous ESEM result, and some of the samples exhibit the expected 
breaches and fractures after cracking in Figure 8.7 (a) and magnification, (b). From the broken 
particles, the inner shells demonstrated regular hollow structures. The thickness of the shells of 
the PCL microspheres was around 1/10 to 1/8 the diameter of the spheres (measured by Image-J 
software). The swelling of the PCL in water (shown in Figure 8.6) was less than 1/5 (2 x 1/10) of 
the diameter of the original spheres and could be attributed to the residual of PVA on the surface 
of the spheres.  
 
8.3.3Morphology and property analysis of MP microspheres 
From section 8.2.1, power number is more stable at higher mixing speeds and PCL6 particles are 
relatively smaller at 23.6 NP mixing condition by homogenizer, which offers a relatively larger 
surface area for other applications. Consequently, the mixing condition, 6000 rpm with NP at 23.6, 
was chosen for MP formulation. Property analysis was undertaken following particle formation 
and morphology observation. Characterisations of MP microspheres were performed with an 
ESEM connected to an Energy Dispersive Spectrometer (EDS) are shown in Figure 8.8 and 
Table 8.3. The morphologies of MP2 and MP6 are displayed in Figure 8.8 (a) and (b). According 
to the results, MP2 and MP6 particles are well dispersed and stable in spherical shape. In Figure 
8.8 (c), shows disruption on the particle surface when in a dry environment, which corresponds to 
the ESEM results.  
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Figure 8.8 Micrographs of (a) MP2, (b) MP6, (c) surface and (d) inner shell.  
 
Table 8.3 Contents of MP particles observed by EDS analysis. 
 C O Fe Total Weight % 
Spectrum 1 (c) 89.3 10.7 0 100 
Spectrum 2 (d) 91.7 7.6 0.7 100 
 
 
MP6 was also crushed in Figure 8.8 (d) in order to collect spectra from the inner surface. The 
results show that there was no iron on the surface of MP particles in (c), but 0.7 % on the inner 
shell of the sample in (d). According to the EDS results, the majority of magnetite nanoparticles 
were assumed to be encapsulated inside PCL microspheres and only a small amount of magnetite 
appeared on the surfaces of the microspheres. In a report by Hamoudeh and Fessi, PCL-magnetite 
microparticles were formed by an emulsion evaporation method, similar to the formulation used 
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in this investigation, which confirmed the encapsulation of magnetite within PCL (Hamoudeh 
and Fessi, 2006). However, the elemental analysis by EDS is not quantitatively precise for 
element concentration especially elements with low atomic numbers (Buck et al., 2004). The 
electron beam was manually localized on the target area within the range of view reached from 
ESEM (Kutchko and Kim, 2006). Therefore, EDS can be used to identify the existence of the 
elements by presenting the peaks of different intensities, but the concentrations of elements 
should be confirmed by another means. Table 8.3, the EDS results show the success of magnetite 
encapsulation within PCL, and the spherical shape of PCL particles did not present a significant 
change in appearance following encapsulation work with magnetite, as shown by ESEM images.  
 
After the elemental identification, schematic illustrations of MP particles are presented by cross-
sections and the images were captured by TEM as shown in Figure 8.9. The micrographs 
illustrated that the magnetite nanoparticles were encapsulated within MP. MP particles are hollow 
in shape as shown in Figure 8. 8. Hollow shaped particles were crushed and some parts of the 
particle were squeezed to one side during the procedure of cutting. In the micrograph, (a) is MP2 
and (b) is MP6 single particles captured by TEM. MP2 and MP6 became oval-shaped due to the 
pressure applied during crushing. The magnetite dispersion in the shell of PCL is clearer in (b); 
individual magnetite nanoparticles can be seen and were surrounded by PCL shell shown as light 
grey matrix. This is evidence that the magnetite nanoparticles were encapsulated inside PCL 
microspheres. 
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Figure 8.9 Transmission electron microscope of cross section through (a) MP2 
and (b) MP6. 
 
The encapsulation of magnetite with PCL was further confirmed by FTIR measurements. To 
compare the differences of IR spectra between MP and PCL, the FTIR results of MP and PCL are 
shown in (a) and (b) separately in Figure 8.10. As shown in the results, the low frequency IR 
spectra, at 400 cm
-1 
to 1000 cm
-1
, suggested the presence of magnetite due to the iron oxide 
structure (Yang et al., 2006). As the arrow indicated in (a), the bond of Fe-O at 582 cm
-1
 was 
assigned to the naked Fe3O4 (Hong et al., 2007). The bulk Fe3O4, appeared by the band at 570 
cm
-1
 and shift between 520 cm
-1
 to 610 cm
-1
 depending on Fe(Π) content (Zaitsev et al., 1999). 
The carbon-oxygen bonds stretching in the region of 700 cm
-1
 to 1500cm
-1
 is from PCL 
components (Meerod et al., 2008); the bands of carbonyl, C=O, at 1722 cm
-1
 and symmetric and 
asymmetric of CH2, at 2865 cm
-1
 and 2941 cm
-1
 separately are also from the PCL (Elzin et al., 
2004).  
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Figure 8.10 Compound analyses of (a) MP and (b) PCL by FTIR. 
 
Following the compositional analysis, the crystalline phase of MP microspheres was identified by 
XRD at 2θ incident angle from 15 to 65 degrees scan. The PCL is indicated by two sharp peaks at 
21 and 24, shown in Figure 8.11 (a). The subsidiary graph inside Figure 8.11 (b) was plotted in 
the range of only from 25 to 55. The peaks of magnetite were indicated by the stars and can be 
seen clearer in the subsidiary graph: magnetite produces peaks which are less clear than PCL due 
to the interference of metallic characteristics of magnetite with the X-ray beam. Nevertheless, the 
appearance of magnetite can still be identified from the subsidiary graph. According to magnetite 
diffraction patterns as shown previously, the 2θ value of magnetite peaks are mainly present 
between 25 to 65, which is shown magnified in Figure 8.11 (b). The X-ray may not be able to 
reach the magnetite particles encapsulated inside PCL, therefore the intensities of the peaks 
presenting magnetite are much weaker than PCL.  It is also to do with the fact that magnetite is 
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nanocrystalline and therefore does not give a strong signal when characterised using XRD. The 
low loading rate of magnetite within PCL is the other reason of the presentation of weak signals 
of magnetite nanoparticles. 
 
 
Figure 8.11 XRD results of (a) MP6 microspheres and (b) subsidiary graph 
magnified for the peaks of magnetite nanoparticles. 
 
8.3.4 Magnetization of MP microspheres 
Magnetizations of MP microspheres were measured by SQUID with a field sweep from -60,000 
Oe to 60,000 Oe at 5 K and 300 K. The magnetization curves of MP microspheres indicated that 
the composites retain the superparamagnetic behaviour as shown in Figure 8.12. The magnetic 
saturation of MP at 5 K and 300 K were 1.22 emu/g and 0.8 emu/g, respectively, which were 
much lower than pure magnetite of 46.7 emu/g but still exhibits superparamagnetic behaviour.  
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Figure 8.12 Magnetization curves of MP microspheres at 5 K and 300 K with 
different magnetic field sweep by SQUID. 
 
Magnetic saturation of MP had a decrease when microspheres were at higher temperature, which 
was assumed to be affected by the encapsulated magnetite. The magnetic saturation of magnetite 
slightly decreased when in a relatively higher temperature environment as demonstrated in 
section 7.3.6. The experimental data can be compared with the calculated value from the 
encapsulation rate of magnetite. The mass fraction of magnetite inside MP is 2.68 %, which 
corresponds to 1.2 emu/g of MP magnetic saturation, which is not a significant difference 
between the experimental data. This indicates that the procedures of MP production caused no 
significant oxidisation of magnetite nanoparticles and maintained the superparamagnetism of MP 
microspheres (Banert and Peuker, 2006). Torcu and collegues reported that the magnetisation of 
ferrogels showed dependence on the amount of magnetite nanoparticles (Turcu et al., 2009).  
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8.3.5 Thermal behaviours of PCL and MP microspheres 
DSC was engaged to investigate the thermal behaviours of MP and PCL polymers with a heating 
rate of 10 °C/min and cooling down to original temperature after holding in the set highest 
temperature for one minute. Two heating up processes, due to the different melting ranges, 
carried on from 25 °C to 60 °C and 25 °C to 100 °C separately for PCL2 and PCL6 polymers and 
their encapsulated microspheres, MP2 and MP6. To observe the energy requirement and melting 
point occurrence, the results present by specific heat (J/g×°C) and temperature (°C) dependence.   
 
 
Figure 8.13 The endothermic behaviour of PCL2 and MP2 microspheres. 
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Figure 8.14 The endothermic behaviours of PCL6 and MP6 particles. 
 
In Figure 8.13, the endothermic curves performed the melting behaviours of PCL2 and MP2 
during the heating process. The melting points of PCL2 and MP2 particles appeared at 47 °C and 
40 °C, respectively. The other type of PCL also displayed the change of thermal behaviours by 
the encapsulated magnetite. The endothermic curves of PCL6 and MP6 polymers are shown in 
Figure 8.14. The significant melting transition peaks of PCL6 and MP6 were both present at 
before 60 °C, but the melting point of MP6, 56 °C, is slightly lower than melting point of PCL6, 
58 °C. Apparently, both MP2 and MP6 melting began with earlier stage than the PCL particles 
without loaded magnetite. The energy requirements (enthalpy) to achieve phase change of both 
MP2 and MP6 are relatively lower than PCL2 and PCL6, respectively. Furthermore, the curves of 
both MP2 and MP6 displayed small amounts of fluctuations indicating impurities, which were 
assumed to be from the encapsulated magnetite nanoparticles. 
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Iron oxides are well known of high stability and the oxidation reaction happens only above 500ºC. 
Although particles at the nano-scale have a greater surface area, and therefore can be oxidised at 
much lower temperatures. The peak indicated oxidisation is higher than 200 ºC (Sanders and 
Gallagher, 2003) (Redl et al., 2004). Furthermore, the DSC results of magnetite nanoparticles 
from chapter 7 performed a stable curve in the temperature sweep between 25 ºC and 200 ºC.  In 
addition, the peaks in the curves of MP2 and MP6 are relatively near the peaks of PCL2 and 
PCL6.  For these reasons, the peak areas of MP2 and MP6 were assumed to be from PCL2 and 
PCL6, respectively.  In the report by Weidenfeller et al, the thermal transport properties, heat 
capacity and density of polymer can be changed by additional metal and oxide particles.  They 
especially noted that magnetite containing polymer shows relatively higher thermal conductivity.  
High thermal conductivity provides high thermal diffusivity, which is responsible for an efficient 
moulding process (Weidenfeller et al., 2004). This can explained the earlier stage of melting 
occurred in MP2 and MP6 than the melting of PCL2 and PCL6. Thermal properties of both PCL2 
and PCL6 are affected by encapsulated magnetite nanoparticles. The appearances of magnetite in 
PCL lead to higher thermal conductivity and diffusivity therefore PCL melting can occur at lower 
temperatures, which can be advantageous for further thermal treatment manipulation of the 
product. 
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8.4 Conclusion 
According to the electron micrographs, PCL2 and PCL6 are stable and exhibit few outward 
changes in both dry and wet conditions; this is advantageous for storage and further in vitro/in 
vivo applications. However, the particles sizes of PCL fluctuated with manufacturing conditions, 
which is assumed to be affected by the stabilisers used rather than by the mixing conditions. The 
PCL were hollow spheres and the presence of magnetite did not significantly change the 
morphology of microspheres. 
 
The results from EDS, FTIR and XRD demonstrated the appearance of magnetite nanoparticles 
in the MP microspheres, which indicates the successful formulation of MP microspheres. The 
majority of the encapsulated magnetite nanoparticles are assumed to be encapsulated within the 
PCL shell, because of the weak peaks of magnetite displayed in the XRD results of MP 
microspheres. The micrographs of the cross sections of MP microparticles are another form of 
evidence of the full encapsulation of the magnetite particles. Therefore, the magnetic saturation 
of MP microspheres was measured by SQUID, and the result indicated MP particles possessed a 
superparamagnetic behaviour. The thermal properties of PCL2 and PCL6 have changed by the 
encapsulated magnetite nanoparticles. The existence of magnetite in MP particles lead to higher 
thermal conductivity and diffusivity and consequently left the PCL melting point at a lower 
temperature which brings a benefit of soft particles with less energy generation and becoming 
mouldable for bone fillers. 
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Chapter 9 The influence of heat treatment on the thermal properties of MP 
microsphere 
9.1 Introduction 
When placed in an external altering magnetic field, magnetite (depending on size) causes a rise in 
temperature due to the hysteresis loss or relaxation. Consequently, magnetite has been used in 
fine particles for the localised treatment of tumours. (Neel, 1949, 1953; Morales et al., 1957). 
Two other papers were published on the loading of magnetite into polymers for drug delivery 
(Zaitsev et al., 1999; Yang et al., 2006). 
 
The objective of this chapter is to use the heat from the encapsulated magnetite nanoparticles to 
soften the MP microsphere. In order to soften the MP microspheres in situ, MP microspheres 
were heated by an alternating magnetic field (AMF). A uniform field has to be produced before it 
can be used to soften the MP microspheres. Following AMF treatment, the physiochemical 
properties of the MP microspheres may be different as a result of the phase change induced by 
heating.  Observations of morphology and thermal properties of the MP particles were 
undertaken after the AMF treatment. In addition, heating of the encapsulated magnetite in the 
polymeric matrix was demonstrated by a controllable source of energy, a microwave. Since 
magnetite produces heat when exposed to microwaves (Kirschvink, 1996), microwaves were 
used to control heating within the matrix.  
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9.2 Material and method 
The MP particles were formed by the evaporation emulsion method as described in section 8.2 
and were characterised according to the technology used in section 8.3. In comparison to PCL 
microparticles, the resultant MP particles have relatively low melting points due to the 
encapsulated magnetite providing a higher thermal conductivity. Heat treatments were carried out 
to soften the polymers using two heating devices; an AMF and a microwave. The thermal 
behaviour of MP microspheres was measured using DSC, and the results were converted to the 
crystallinity degree of PCL polymers. The altered crystallinity was used as an indication of the 
property change and therefore the heating of the encapsulated magnetite.  
 
9.2.1 Heat treatment by AMF 
Heat treatments for MP microspheres were undertaken with different concentrations of magnetite 
within PCL microspheres. The AMF device was specifically designed to generate a magnetic 
field at a low power and was applied to soften the MP microspheres. The schematic diagram of 
the AMF is shown in Appendix 1. In a joint project (undertaken by Mr. R. Dickerson and Dr. S. 
Hillmansen, School of Electronic, Electrical and Computer Engineering) a power supply inverter 
was modified to be capable of controlling the electric potential (voltages, V) and the resonance 
frequencies (Hertz, Hz). The power controlled and converted by the inverter was subsequently 
connected to a conductor to create a magnetic field.  Different field densities (milli-tesla, mT) 
were generated by controlling the power and frequency. The magnetic field density of AMF was 
determined by a Gauss meter (for air gap field) (Fluke 289 True-RMS Logging Multimeter, Fluke 
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Co., USA). The current yield in the electric circuit can be observed and represent by mini-ampere 
(mA) from the oscilloscope (LeCroy 9304A, LeCroy Ltd. USA). 
 
The sample was placed between the two cores of the conductor with the magnetic field. The 
distance between the two cores (described as the air gap) is one of the factors affecting the field 
density. Therefore, the effect of gap size on field density was investigated. An Infrared (IR) 
thermal sensor (Micro-Epsilon, UK Ltd.) and a thermocouple were employed to monitor the 
temperature of the samples and the conductor, respectively. 
 
The AMF is capable of generating several field densities, which can subsequently soften MP 
microspheres without the additional heating equipment. The thermal property difference of the 
polymers before and after being exposed to the magnetic field was used to define the success of 
the AMF treatment. 
 
 9.2.2 Heat treatment by Mini-microwave 
A mini-microwave (Discover, S class, CEM Co., US) was used to detect the temperature 
fluctuation during the heating treatments (infrared sensor, programmable from 0 °C to 300 °C). 
This section focuses on the effects of magnetite quantity on altering temperature during the 
microwave heating procedures. Sample MP6 with various encapsulation percentages of the 
encapsulated magnetite were employed to demonstrate the temperature charge during the heating 
process. The heating processes were carried out using 20 watts (W) and 40 W for 20 seconds and 
47 seconds respectively. The MP samples were dispersed in distilled water with the controlled 
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concentration of 5 mg/ml and the liquid was added into a glass tube containing distilled water for 
measurement. 
 
9.3 Results and Discussions 
The first part of this section is the results of field densities that were derived from the AMF with 
altered gap size, frequency and power. In the following parts are the thermal properties and the 
morphologies of the MP particles (before and after the heat treatment). 
 
9.3.1 Field density of the AMF 
The use of an alternating magnetic field generated by high power and frequency supply (up to 
mega Hz) for hyperthermia applications has been widely reported (Okawa et al, 2006; Hergt et al, 
2004). The treatment by a strong AMF or heater may be harmful for neighbouring tissues. This 
study focuses on using an AMF generated by a limited power supply to soften particles, which 
offers a cheap and low power requirement method for polymer melting for bone replacement.  
 
In order to obtain identical AMF conditions as a means of heating the MP particles, AMF was 
generated at different gap distances and various combinations of frequencies and power. Figure 
9.1, shows the magnetic field generated under a steady electric potential of 80 V, and various 
frequencies with different gap size. At different gap sizes, the presence of the air gap had an 
effect on field density. The field densities, displayed a decrease with gap width (from 1 mm to 
3.5 mm, respectively). Stronger field strength was generated when combing a lower frequency 
with a steady supply of electric potential. The four curves indicate that the greater the gap size, 
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the lower the field density. By comparison, in the weaker field densities derived from 200 Hz and 
400Hz, the gap effect was less notable than in the greater field densities derived from 20 Hz and 
100 Hz. 
 
 
Figure 9.1 Field densities at different gap distances at 80 V and various 
frequencies. 
 
In Figure 9.2, magnetic fields were generated by combining several of frequency and voltages 
generating. As the gap size of 1 mm was resulted from the sample volume, the smallest gap size 
that can be controlled in this device, 1.5 mm, was selected as a consistent air gap in Figure 9.2.  A 
similar trend was observed to that can be seen in Figure 9.1, a stronger field density occurred 
when a lower frequency was combined with a steady supply of electric potential and the gap 
distance. Again, the trends are much more obvious in the low frequency curves. On the other 
hand, higher voltage inputs with a steady frequency gave higher field strength. 
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Figure 9.2 Field densities at different voltage and frequency with a consistent 
gap of 1.5 mm. 
 
From Figure 9.1 and 9.2, it can be seen that higher field density results when reducing frequency.  
A fundamental of electromagnetic field is that high voltage leads to a stronger field density. By 
contrast, the field density is lower with a larger air gap at constant electric potential.  
 
A smaller gap width generates a stronger magnetic field than a larger gap. However, higher 
electric potential derived electromotive currents, (shown in Figure 9.3) resulted in greater 
electrical resistance that leads to an undesired temperature rise in the coil (Yamaguchi et al, 
2005). The temperature increase of the coil is harmful for devices located in the AMF, and more 
importantly will transport the heat to the conducted core and affect the results of thermal 
properties of MP microspheres. 
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Figure 9.3 Current recorded at 20 Hz and different voltage with a 1.5 mm gap. 
 
Demonstration of the temperature rise in the coil is shown in Figure 9.4. The increase of the coil 
temperature was evaluated using IR sensor, observed during the field generated by combing a 
high voltage and a low frequency (80 V and 20 Hz). The peak is an artefact of the equipment. 
The core showed a rise in temperature of 2 °C in ten minutes during the field generation. It 
should be noted that the field strength is relative stronger at 20 Hz according to Figure 9.1. 
Therefore, the temperature change of the conducted cores during the field was recorded by 
inverting the electric frequency at 20 Hz with the various voltages. In Table 9.1, the AMF was 
generated by inverting 20 Hz with 80 V, 30 V and 20 V, and the temperature of the conducted 
core was measured by a thermocouple.  
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Figure 9.4 IR sensor measured temperature at 20 Hz and 80 V.  
 
The MP6 particles were placed in between the cores of the AMF equipment and the sample 
volume gave a gap of 0.08 mm, which is under the minimum of the capable range of IR detection; 
therefore the sample temperature was measured by the IR sensor before and after AMF treatment.  
A. B and C are the result groups of the AMF generated at 80 V, 30 V and 20 V with a constant 
frequency, 20 Hz, as show in Table 9.1. The temperature of the cores increased in the AMF, and 
the temperature increase rates of the AMF at 80 V and 30 V are higher than the AMF at 20 V. 
The AMF generated at 80 V was used to observe the temperature increase without loading a 
sample. The result of sample B exhibited a similar temperature rise (0.17 °C/min) and the sample 
temperature increase rate (0.15 °C/min); which demonstrates a slight difference and indicates that  
the sample heating was affected by the warming core. On the other hand, the result of sample C 
exhibited a relative low temperature rising rate to that of the conducted core, and the final 
temperature of the sample (MP6) was higher (19 °C to 21.5 °C) with a temperature rise rate of 
0.025 °C/min. 
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Table 9.1 Temperature increase during AMF generation at 20 Hz. 
 A B C 
Electric potential (V) 80 30 20 
Field density (mT) 325 114 74 
Temperature 
rise rate (°C/min) 
         Core 0.2 0.17 0.003 
       Sample - 0.15 0.025 
 
 
Therefore, the magnetic field generated by 20 Hz and 20 V demonstrated relatively ideal 
conditions, with less undesired heat from the warming coil and therefore the conducted cores; the 
air gap should be as small as possible for higher field strength (Figure 9.1). However, the volume 
of sample exhibits space between the conducted cores and resulted in an air gap in the magnetic 
field. The smallest gap of 0.8 mm, was a result of sandwiching the MP microspheres between two 
plastic slides and placing them onto the conducted core, and the smallest controlled air gap here 
is 1.5 mm in width. The field densities of the AMF was varying frequency at 20 V with gaps of 
1.5 mm and 0.8 mm respectively are shown in Figure 9.5. As previous results shown (Figure 9.2), 
the field strength is stronger when a lower frequency is used, and the field observed at 20 V and 
20 Hz is the relative ideal condition (Table 9.1). According to the results in Figure 9.5, the field 
density derived with the 0.8 mm gap is approximately 5 times greater than the field density 
derived with the 1.5 mm gap. Consequently, the ideal conditions for generating the AMF are 
combining the frequency at 20 Hz and the electric potential at 20 V with an air gap of 0.8 mm.  
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Figure 9.5 Field strength yield at 20 V and varying frequency for the two air 
gaps, 1.5 mm and 0.8 mm. 
 
Collaborating with Electronic, Electrical and Computer Engineering, the AMF equipment was set 
up at 20 Hz and 20 V due to the relative high field strength and the minimisation of device coil 
warming. This set up was used for the following heat treatments and drug release research.   
 
9.3.2 Morphology  
The morphologies of the MP particles before and after AMF treatment were observed by loading 
the MP particles into an irregular shape (model of bone defect) and placing in the magnetic field.  
The macrographs in Figure 9.6, (a) to (e), illustrate the softening and melted particles filling the 
irregular cavities and importantly the polymer could be moulded into any shape. Figure 9.6 (a) 
and (b) are the macrographs of MP6 (a) before and (b) after AMF treatment and were attached to 
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a 2D-mold graph of bone defect to illustrate that the softened particles can fill the irregular 
trauma. Figure 9.6 (c) shows the 3D-mold shape of unlimited concave to allow filling of more 
particles, (d) demonstrates the loose particles that have been spread onto the model shape before 
AMF treatment; and Figure 9.6 (d) presents the polymers filling the pattern after the AMF 
treatment and after the model shape was removed. The resultant particles in (b) are brown 
agglomerates, which are different between the loose pale brown particles in (a). The resultant 
brown colour displayed in (b) is assumed from the encapsulated magnetite particles exposed after 
the PCL matrix fused together. Similar to Figure 9.6 (a), the particles were loosely dispersed in 
the shape shown in (d); and then after the AMF treatment, became the well-shaped pattern after 
the model template was removed, shown in (e). The resultant particles in (e) also displayed a 
darker brown colour.   
 
 
Figure 9.6 Macrographs of MP6 before and after AMF treatment. 
(a) non-treated MP6 above a 2D-mold figure of bone defect, (b) AMF-treated 
MP6, (c) the 3D Perspex mould, (d) the loose particles spread onto the model 
shape before AMF treatment and (e) shaped pattern after AMF treatment and 
the removal from the mould. 
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The dispersion of magnetite inside the MP microspheres was detected by Micro-CT before and 
after the AMF treatment. The 2D pixel of micro-CT was correlated to the material density and the 
resultant 2D map reveals the material phases within the specimen (Ho and Hutmacher, 2006).  
Magnetite nanoparticles were sprinkled around an agglomerate of PCL6 inside a container as 
shown in Figure 9.7 (a). The PCL and magnetite are seen as orange and purple, respectively, as a 
result of the two different densities within the particles. Figure 9.7 (a) was therefore used as the 
colour index for future images from the micro-CT. MP6 microspheres in Figure 9.7 (b) 
demonstrates the dispersed particles within the container, and (c) shows the micro-CT scan. The 
Micro-CT scan recorded the samples layer by layer, up to approximately 250 layers. Figure 9.7 (c) 
and (d) are the upper and lower layers of the sample, respectively. The two images display the 
orange and purple colours mentioned above. The presence of these colours indicated that the 
particles contain both PCL and magnetite. This indicates that magnetite nanoparticles are 
dispersed within the microspheres. The resolution of Micro-CT is about 5 microns and the 
present of nanomagnetite in MP maybe due to the porosity of MP agglomerates and the damaged 
MP after heat treatments. 
 
 
Figure 9.7 (a) Magnetite and PCL separately; MP of (b) X-ray images and (c) 
from upper and (d) lower layers of MP6 microspheres.  
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The AMF treated MP microspheres are shown in Figure 9.8. Figure 9.8 (a) shows the raw image 
of a section of fused MP agglomerate (hold by seal tape for micro-CT measurement) as 
demonstrated in Figure 9.6 (e). The loose particles cohered into agglomerate after AMF treatment 
in Figure 9.8 (b) and (c) (the upper and lower layers). These exhibited the two major colours, 
orange and purple, which indicates MP microspheres fused after softening during the AMF 
treatment. By contrast to previous loose particles (Figure 9.7 (c)), the orange area appears more 
dominant with purple spots representing partially assembled magnetite within the compound. The 
assembling of magnetite is assumed to be attributed to the attraction of the embedded magnetite 
particles exposed after the PCL particles softened and melted in the presence of the magnetic 
field. The melting and formation of agglomerating is a fundamental requirement in desired filling 
materials, and is evident here. 
 
 
Figure 9.8 (a) agglomerate (b) upper and (c) lower layer of AMF treated MP.  
 
From the macrographs and Micro-CT results, it can be assumed that the MP microspheres have 
been softened by the AMF treatments. Once softened, the solid phase and spherical shape of the 
MP microspheres were expected to change and ESEM images were used to illustrate this in 
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support for AMF-treated MP. Figure 9.9 shows (a) the whole agglomerate, (b) the fused area, (c) 
the melted MP with some un-melted particles, (d) a layered agglomerate, (e) disrupted MP6 
microspheres, (f) disrupted MP2 particle microspheres, (g) cohered MP microspheres, (h) loose 
microspheres, (i) damaged microspheres, (j) magnification  of (i), (k) a single domain of MP6 
and (l) a damaged single domain of MP6. A red square indicates the disrupted area of the 
microspheres after AMF treatment. 
 
Figure 9.9 (a) to (f) are treated by AMF and observed by ESEM individually. The final six 
images, Figure 9.9 (g) to (l), are from the same sample at different ESEM magnifications. AMF 
treated MP microspheres either cohered in agglomerates or damaged particles. The images 
exhibit disruptions to the surface of several microspheres in both MP6 (e) and MP2 (f) sample, 
which are not observed from the images of both MP2 and MP6 microspheres before AMF 
treatment (Figure 8.8). Images (g) to (l) were captured at varying magnifications to demonstrate 
clearer views of the structural defect on the microspheres. Image (g) shows the cohered particles; 
and (h) shows a few loose particles around the cohered agglomerate. Although the loose 
microspheres in (h) were not softened as the cohered counterparts, the surfaces shows disruption 
as a result of AMF heating. Image (k) is a single microsphere; the central of the surface displays a 
collapsed area. Additionally, images (i), (j) and (l) were captured from magnification of the 
cohered area of (g). The images illustrate damaged microspheres with the particle shells ruptured 
and becoming non-spherical in shape. These ruptured MP2 and MP6 microspheres are presumed 
to be damaged by the local heat generated from the embedded magnetite. These microspheres 
were softened, and therefore clustered into an irregular agglomerate upon cooling. 
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Figure 9.9 Micrographs of MP microspheres after AMF treatment: 
(a) the whole agglomerate, (b) the fused area, (c) the melted MP with some un-
melted microspheres, (d) a layered agglomerate, (e) disrupted MP6 
microspheres, (f) disrupted MP2 microspheres. 
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Figure 9.9 Micrographs of MP particles after AMF treatment: (g) cohered MP 
microspheres, (h) loose microspheres, (i) damaged microspheres, (j) 
magnification of (i), (k) a single domain of MP6 and (l) a damaged single 
domain of MP6. 
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In conclusion, the morphologies of MP microspheres from macrographs (Figure 9.6 and 9.8) and 
micrographs (Figure 9.9) indicated successful heating of the MP particle microspheres during 
AMF treatment. Further analysis of the thermal properties of the polymer can be used to define 
the difference between PCL (no loaded-magnetite) and MP after AMF treatments, and can 
therefore be used as an indicating of successful the heating caused by embedded magnetite.            
 
9.3.3 Thermal property 
The existence of magnetite within the microspheres may have introduced effects on the three-
dimensional structure of the polymers, which can lead to polymer instability due to perturbations 
weakening of the van der Waals interaction between the polymer chains (Vijaya et al., 2000). 
The mechanical properties of the polymers can be determined in terms of the degree of 
crystallinity (Kong and Hay, 2002). Crystallinity degree is calculated from Equation 9-1, where 
∆HPCL is the thermodynamic melting enthalpy of 100% crystalline PCL and ∆H is the melting 
enthalpy of the sample (J/g). The value of ∆HPCL is 136 J/g (Crescenzi et al., 1972; Saad et al., 
2010). 
 
                             ⁄                      9-1 
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Figure 9.10 shows the change in crystallinity of PCL2 and MP2 particles before (grey bars) and 
after (dark grey bars) the AMF treatments, respectively. MP2 has 7.5 % of magnetite 
encapsulated in the microspheres (determined by TGA). Thermal properties of PCL2 and MP2 
are shown in Table 9.2. In the case of non-AMF treatment, PCL2 (the first grey bar) exhibits a 
higher degree of crystallinity than MP2 (the second grey bar) where the crystallinity of PCL2 and 
MP2 are 66.6 % and 56.8 % respectively. The crystallinity is approximately 10 % lower after 
encapsulation of magnetite nanoparticles. The melting temperature of MP2, 40.4 °C, is much 
lower than the melting point (47 °C) of PCL2 after loading magnetite into the polymer, which is 
induced by the heat conductivity of magnetite as discussed in Chapter 8.  
 
 
Figure 9.10 Crystallinity changes of PCL2 and MP2 microspheres before and 
after AMF treatments. 
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After AMF treatment, the crystallinity of PCL2 (the first two bars) falls slightly (by 6 %) after 
treatment by AMF, whereas MP2 (the last two bars) shows an increase of crystallinity. By 
contrast, the melting points of both PCL2 and MP2 after treatment by the AMF are 49.1 °C and 
42.6 °C respectively, which have increased by approximately 2 °C for both PCL2 and MP2. The 
difference in crystallinity after treatment by AMF indicates a 6 % loss for PCL2 and a 15 % 
increase of MP2. The crystallinity change is obtained from Equation 9-2, where CAMF is the 
crystallinity of sample after treatment by AMF and the CNO is the crystallinity of sample without 
AMF treatment. 
 
                       
(         )
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Table 9.2 Thermal properties of PCL2 and MP2 particles before and after 
AMF treatments.  
 
MP (%) 
Tm (°C)
* Crystallinity (%) Crystallinity 
change (%) No AMF No AMF 
0 47.3±0.1 49.1±0.3 66.6±1.3 62.3±0.4  -6.4±2.4  
7.5 40.4±1.5 42.6±0.6 56.8±0.7 65.7±1.3  15.8±0.2  
Tm (°C)
*
: recorded by DSC. 
 
The thermal effects of AMF can be better understood by a comparison of the two types of PCL 
and MP microspheres.  The mechanical properties affected by thermal fusion of PCL6 and MP6 
particles after AMF treatment are also demonstrated.  
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In Figure 9.11, the degrees of crystallinity for magnetite encapsulation rates of MP6 (0 %, 3 % 
and 5 % respectively) are shown for before and after AMF treatments. The thermal properties and 
crystallinity change for PCL6 and MP6 are presented in Table 9.3. 
 
 
Figure 9.11 Crystallinity changes of PCL6 and MP6 microspheres before and 
after AMF treatments. 
 
Table 9.3 Thermal properties of PCL6 and MP6 microspheres before and 
after AMF treatments. 
 
MP (%) 
Tm (°C) Crystallinity (%) Crystallinity 
change (%) No AMF No AMF 
0.0 58.1±0.3 58.1±0.3 58.9±0.2 58.9±0.2 0.0±0.0 
3.0 53.9±0.8 58.0±0.6 48.1±1.8 65.9±7.7 37.0±15.0 
5.0 56.3±0.8 62.1±0.4 45.6±2.1 67.2±0.3 47.4±6.1 
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Before the AMF treatment, the composite particles, 3 % and 5 % MP6, have a lower degree of 
crystallinity than the pure PCL6 demonstrated by the three light grey bars, shown in Figure 9.11. 
The degrees of crystallinity of the two MP6 samples (48.1 % and 45.6 % individually) are both 
lower than the degree of PCL6 (58.9 %). In addition, the melting point of two MP6 samples were 
53.9 °C and 56.3 °C respectively, which are both lower than the melting point of PCL6 (58 °C). 
This complies with the results for the MP2 microspheres were the heat conductivity of the 
encapsulated magnetite, which was improved and therefore leads to an earlier melting stage. 
 
In Figure 9.11 and Table 9.3, the degree of crystallinity after treatment by the AMF exhibits 
marked differences in the results of 3 % and 5 % MP6, but not for the result of PCL6. The 
melting points and degrees of crystallinity of PCL6 (0.0 %) show a difference of less than 0.1 % 
between the AMF treated and non-treated samples. By contrast, after treatment by the AMF, 
there is a 37 % and 47.4 % increase in the crystallinity for the 3.0 % and 5.0 % MP6 samples, 
respectively. The increases are also apparent in the melting temperatures of the two MP6 
specimens after the AMF treatment.      
 
According to a report by a group of researchers, the highly ordered structures of polymers are 
strongly affected by thermal history and the crystallinity of PCL chains increases during heating 
(Hatakeyama et al., 2000). An inference can be that there was a heating effect to the two types of 
MP particles during the AMF treatment. By contrast, the crystallinity of PCL6 shows no notable 
difference after the AMF treatment. The heat generated from the encapsulated magnetite can be 
linked to change in the thermal and crystal structure of the polymers.  
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The decrease in MP2 crystallinity after AMF treatment is assumed to be from the effects of 
conductor temperature. According to Figure 8.11 and Figure 8.12, the melting temperature of 
PCL2 particles is much lower than PCL6 particles. Although the melting point of PCL2 particles 
is 47 °C, the melting process of polymer occurs in a relatively wide range compared to single 
domain materials (Kong and Hay, 2002). The earliest stage of PCL2 melting starts from 35 °C as 
seen in Figure 8.11, and the partial phase disturbance is assumed to have occurred earlier than the 
melting. Additionally, partially heated PCL2 can be observed after the AMF treatment even when 
the temperature of the conducted core is controlled at room temperature, as shown in Figure 9.12 
(a). Figure 9.12 (b) shows no obvious morphological change in PCL6 particles after the AMF 
treatment. According to the recrystalline points of PCL2 and PCL6 (21 °C and 32 °C respectively) 
from DSC measurements (Figure 9.13), partially melted-PCL2 is not able to process the 
recrystallisation stage at room temperature over 22 °C.  This is possibly due to the crystallinity of 
PCL2 becoming lower after partially melting by the AMF treatment. The crystallinity of MP2 
after AFM treatment has increased but which was not as high as the rising ratio of the two MP6 
specimens (as compared Table 9.2 and Table 9.3). Therefore, the altered thermal properties of 
PCL2 after the AMF treatment indicate that the PCL2 has been affected by warming of the core.  
 
 
Figure 9.12 Macrographs of the AMF treated (a) PCL2 and (b) PCL6. 
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 Figure 9.13 Recrystallization of PCL2 and PCL6 during cooling process. 
 
In conclusion, a decrease in both the melting points and degrees of crystallinity, which was seen 
for exhibited in MP2 and MP6, respectively. These results are due to the encapsulation of 
magnetite nanoparticles in PCL, which change the thermal properties after loading the magnetite 
(Weidenfeller et al., 2002). 
 
MP particles after heat treatment show morphological and crystallinity changes, which provide 
evidence of a phase change as a result of softened or melted structures. The main aim of this 
thesis is to produce softened PCL by the heat generated from the encapsulated magnetite by 
means of AMF treatment. The mechanism of heat generation by magnetite in AMF is still a point 
of scientific discussion.  Hysteresis loss and relaxation loss are the two key factors of the heat 
generated by magnetite particles in an AC magnetic field (Hergt et al., 1998). The heating ability 
of larger magnetic particles (100 nm or larger) mainly results from hysteresis loss, which is 
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strongly size dependent (Kim et al., 2005). Ma and colleagues suggested that relaxation loss 
becomes more important for the heating from magnetite when the magnetite particle is smaller 
than 46 nm and has superparamagnetism (Ma et al., 2004). Larger magnetite particles (over 46 
nm) exhibited size dependence on the hysteresis loss and therefore the temperature of magnetite 
particles. However, smaller magnetite particles (7.5 nm and 13 nm) exhibited very little 
hysteresis losses but higher temperature rising curves.  
 
Néel relaxation and Brownian motion are the two phenomenon of energy loss of single domain 
particles, consequently resulting in particles heating. The magnetic moments of 
superparamagnetic particles rotate in an AC magnetic field, where the rotation of the particles 
overcome the energy barrier for reorientation. Therefore the energy is dispatched when the 
particle moment relaxes to its equilibrium orientation, which is known as Néel relaxation. 
Alternatively, the rotation of the entire magnetite particle in the AMF is called Brownian motion 
(Mornet et al., 2004). The heat generation in MP spheres is presumed to be from Néel relaxation 
rather than from Brownian motion because the magnetite was embedded in a solid phase with 
higher viscosity (compare to ferro-fluid), and subsequently, there was less space for particles to 
rotate (Kötitz et al., 1999).  According to the report of Okawa, the heating ability of magnetite 
in agar gel is mainly from Néel relaxation and the Brownian relaxation is neglected due to the 
time of Brownian relaxation is much longer (10
3
 times larger than the value of Néel relaxation) in 
the higher viscosity environment (Okawa et al., 2006).  
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9.3.4 Heat treatment by Mini-microwave  
In order to show a change in temperature by the encapsulated magnetite particles during the 
heating process, the MP particles were heated by a mini-microwave. The relationship between the 
amount of encapsulated magnetite and the temperature difference was compared by observing the 
rising temperature by per unit of the specimen (mg). Figure 9.14 demonstrates the increase of 
temperature for PCL6 (0 %) and the two MP6 (3 % and 5 %) particles during the microwave 
heating process at 20 W for 20 seconds. The increasing rate of temperature of polymer is higher 
when more magnetite is encapsulated, for example, 0.5 °C/mg, 0.7 °C/mg and 1 °C/mg for PCL6, 
3 % MP6 and 5 % MP6, respectively.   
 
 
Figure 9.14 Heating particles by mini-microwave at 20 W for 20 seconds.  
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The heating effect of the encapsulated magnetite also exists in an altered power input in the mini-
microwave. Figure 9.15 shows the change in temperature when the microwave was operated at 
40 W for 47 seconds. The temperature increase with a higher power input was exhibited in all the 
specimens. By contrast, the two MP samples display an increase in temperature which was 
generally larger than the temperature increase of the PCL6 sample during the heating process. 
The rising temperature rates of PCL6, 3 % MP6 and 5 % MP6 are 6.6°C/mg, 6.1 °C/mg and 8.1 
°C/mg, respectively. The temperature of MP spheres increased with the amount of encapsulated 
magnetite during the microwave heating. This phenomenon has been addressed in the literature 
as microwave absorption by iron compounds releases the energy to boost the heating process 
(Acierno et al., 2004). The microwave also offers an alternate method for melting polymers 
containing magnetite and the rise in temperature can be controlled by the mass of magnetite.    
 
 
Figure 9.15 Heating particles by mini-microwave at 40 W for 47 seconds. 
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Figure 9.16 shows micro-CT images of the resultant polymers after the heating process by 
microwave; (a) shows the melted agglomerate of MP6 and (b) the two images from the layered 
scans.  The microspheres melted and cohered after heat treatment by microwave. Figure 9.16 (b) 
shows the two major colours, orange and purple indicating PCL and magnetite, respectively 
(same colour index as Figure 9.7 (a)). This is similar to the results of AMF treated MP spheres in 
Figure 9.8, the orange area is more prominent than the non-heated particles (shown in Figure 9.7 
(c)) and the purple spots gathered within the compounds. 
 
 
Figure 9.16 MP microspheres after microwave heat treatment (a) agglomerate 
of MP, (b) upper and (c) lower layers of micro-CT scan. 
 
The Micro-CT images of MP6 particles treated by the mini-microwave and the AMF exhibited 
the same results that particles agglomerated due to the polymer melting. This is further evidence 
of demonstration that the MP particles have been successfully softened or melted during the 
AMF treatment. 
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9.4 Conclusion 
The macrographs showed that the MP particles agglomerated after AMF treatment and that there 
was same structural disruption of MP particles. An altered thermal property of polymer is 
important evidence of melting and phase change in a polymer. After the formulation of MP 
microspheres, the decrease in melting point and the degree of crystallinity indicated the 
successful of encapsulation magnetite nanoparticles in PCL2 and PCL6, respectively. After AMF 
treatment, the altered thermal properties and the degree of crystallinity proved that there was a 
heating effect to MP2 and MP6 during the AMF treatment, and the heating is assumed to be from 
the embedded magnetite due to the comparisons of PCL2 and PCL6. The thermal property of 
PCL6 has no notable change after the AMF treatments, but the degree of crystallinity of PCL2 
was slightly altered by the warming core, which can be observed from the image with partially 
phased change (as seen in Figure 9.12).  
 
The uniform AMF (20 Hz, 20 V, 1 hour) successfully derived the magnetic field to induce the 
magnetite heating. The heating of magnetite nanoparticles in the AMF is suggested to be from 
Néel relaxation. Compared to the reported AMF with the sample space in a water-based area (Ma 
et al., 2004; Kim et al., 2005), the uniformed AMF in this thesis is advantageous in that magnetic 
materials can be treated in a dry environment, and therefore the melted polymers can be filled 
into a defect within a sufficient mouldable time. The other advantage of this AMF system is the 
low power requirement (20 Hz and 20 V), compared to devices that use power input up to kilo-
Hz for penetrating depth in vivo (Ito et al., 2002; Asmatulu et al., 2005). The low power 
requirement AMF is beneficial for cost and for open injury, for example, bone trauma. To 
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conclude, MP microspheres can be used to soften PCL polymers by AMF and enable them to be 
potentially used as bone trauma filling.   
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Chapter 10 Drug release of MP microspheres with/without AMF treatment 
and the microbiology activity after release 
10.1 Introduction 
The second objective of this thesis is to soften MP particles and release drugs from the MP 
microspheres, as described in Chapter 5. Therapeutic treatment using drug release of polymeric 
system, which reduce side effects and enhance efficacy is advantageous than the injection method 
and controllable dose and rate (Richardson et al., 2001). Polylactic acid derived polymer, for 
example, PCL, is interesting due to its biocompatibility and degradability, which has been well 
investigated of many types of scaffolds and biomaterials using as a drug carrier (Habraken et al., 
2007, Wang, et al., 2007).  
 
Hyperthermia combining drug release of magnetite composites have attracted interest and is 
under development by many research groups (Yang et al., 2006, Babincova et al., 2001). In 
addition, Gentamicin is one of the commonly used aminoglycosides as antibiotics in anticancer 
therapy, which is heat stable and is able to kill most of the gram-positive and some gram-negative 
bacteria (Yoshizawa et al., 1998, Casemore, 1967).  
 
The uniform AMF was used to induce the polymer softening by the magnetite heating and 
consequently carrying out the release of the encapsulated gentamicin. 
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10.2 Materials and Methods 
The first two parts of this section describe the preparation of drug-loaded particles and the drug 
evaluation method. This is followed by the gentamicin drug release with and without AMF 
treatments. The heat treatment by AMF is using the identical condition from Chapter 9. Finally, 
the microbiological activity of the gentamicin loaded spheres is used to illustrate the efficacy of 
the AMF -treated drug loaded MP spheres.  
 
10.2.1 Preparation of gentamicin loading MP microspheres 
The preparation of gentamicin loaded MP microspheres (GMP) is similar to the formulation of 
MP microspheres in section 8.2. A mixture of water dispersed magnetite and gentamicin sulphate 
(GS) (10 mg) (Sigma) was added into a solution of PCL dissolved in dichloromethane. The 
resultant liquid was sonicated for 5 minutes and followed by high speed mixing (23.6 Np) into 2 
% PVA solution to form w/o/w emulsion. The rest of the procedures are same as described in 
section 8.2. 
 
10.2.2 Evaluation of encapsulation rate and GS release of GS in GMP spheres 
The fluorescence method is the most common assay for GS evaluation. The basic theory is to 
determine the UV absorption of a fluorescent isoindole resulting from the reaction between the 
amino groups in the gentamicin molecule and o-phthaldialdehyde (OPA) (Chang et al., 2006). 
Gubernator and colleagues have reported a simple and sensitive method for gentamicin 
evaluation, which was used to evaluate the GS released from GMP particles in this thesis 
(Gubernator et al., 2006). The first step in this assay is to prepare the OPA reagent; 0.5 ml of 
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methanol was used to dissolve 0.1 g of o-phthaldialdehyde (Sigma), and then 9.5 ml of 0.4 M 
boric buffer at pH 10.4 was added and mixed. 0.2 ml of 2-mercaptoethanole was added and the 
resultant solution was adjusted to pH 10.4 by neat potassium hydroxide (Sigma). The boric buffer 
was prepared by mixing 24.7 g of boric acid (Sigma) in 900 ml of distilled water, and kept at 4 
°C after adjusting the pH to 10.4 by neat potassium hydroxide. The OPA reagent is stable at 4 °C 
for only 2 to 3 days, thus fresh OPA reagent was prepared every two days in this research.  
 
Once the OPA reagent is ready to use the following procedures were undertaken. First, 0.85 ml of 
distilled water was used to form 1 ml aliquot with 0.15 ml of specimen and was followed by 
mixing with 0.6 ml of methanol. 0.1 ml of OPA reagent was added into the sample and 
vigorously mixed. The resultant solution was incubated for 10 minutes at room temperature 
before measurement. UV absorbances of samples were measured by a UV spectrophotometer 
(Uvikon 922, Kontron Instruments, Northstar Scientific) at 332 nm. A calibration curve was built 
using gradient concentrations from 0.5 μg to 4 μg of GS. The determination coefficient (R2) of 
the calibration curve is 0.97 as shown in Appendix 12.2 
 
To determine the encapsulated GS, 10 mg of GMP microspheres were dissolved in 5 ml 
dichloromethane and the drug was extracted by 10 ml of 0.01 M phosphate buffer solution (PBS, 
Sigma). The resultant liquid exhibited two phases following 5 minutes sonication, as shown in 
Figure 10.1. The upper layer was the aqueous phase of the extracted GS in the PBS solution, and 
the bottom layer was the organic solvent, dichloromethane, and the dissolved PCL. The 
magnetite nanoparticles represent brown colour at the interface, which also another provides 
evidence that the MP microspheres had been incorporated into the formulation. The aqueous 
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solution was collected from the upper layer liquids and was stored at 4 °C prior to the 
quantitative by OPA assay.  
 
                    
Figure 10.1 GMP microspheres after dissolving in dichloromethane to 
evaluate the release of GS in PBS.  
 
10.2.3 GS release and heat treatment  
The drug release from GMP loaded microspheres was assessed with and without AMF treatment. 
AMF treatments were undertaken at the identical conditions in Chapter 9, at 20 Hz and 20 V for 
one hour. The AMF-treated and non-treated GMP microspheres were immersed in 3.5 % (w/v %) 
PBS solution and were retained in a 37 °C shaker during the period of drug release. An immersed 
aliquot (150 μl) was taken for release evaluation at time intervals (24 hours) and refreshed using 
the same amount of PBS solution (Wang et al., 2007).   
 
10.2.4 In vitro evaluation of microbiological activity of released gentamicin 
One of the important factors of drug release work is the maintenance of the bioactive molecules 
entrapped in the polymeric matrix (Chang et al., 2007). E. coli (10,000 NCIMB Ltd., UK) was 
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selected as a pathogenic microorganism to demonstrate the antibacterial activity of the released 
gentamicin. 
 
Using a sterile loop, E. coli was transferred into sterile nutrient broth (CM0067, Nutrient Broth 
No. 2, Oxoid Ltd., UK). The broth was incubated at 37 °C for 24 hours prior to being diluted of 
10
-4
 times. 200 μl of the dilution culture was spread evenly onto a nutrient agar plate (BO0336, 
Oxoid Ltd., UK) and after 10 minutes setting time a GS-loaded paper disk (13 mm) was placed in 
the centre. The GS-loaded paper disc had been prepared from 30 μl of the immersed aliquot 
(section 10.2.3) which was allowed to soak onto the paper disk before being placed in the agar 
plate with E. coli. The drug release rate and antibacterial efficacy were compared for GS from 
non-treated and AMF-treated GMP microspheres on the first day of release. Drug free PBS 
solution was used as a control for the microbiological activity. 
 
10.3 Results and Discussions 
This result section includes four parts: the morphologies of the formulated GMP microspheres, 
the quantification of the encapsulated GS, the drug release measurement, and investigation of the 
antibacterial ability of the released GS. 
 
10.3.1 Morphology of the GMP microspheres 
The morphology of the GMP microspheres were assessed by ESEM and EDS for composition 
analysis. The GMP microspheres appeared spherical in shape. The GMP spheres in Figure 10.2 (a) 
shows in uniform shape and are similar size as MP microspheres (shown in Figure 8.8), (b) 
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shows a single sphere with rough surface. The GMP spheres exhibit polydispersion (seen Chapter 
8) as seen in Figure 10. 2 (c), and the broken domain, (d), was used for compounds analysis by 
EDS. 
 
 
Figure 10.2 Morphologies of GMP microspheres, (a) collection of GMP, (b) 
single GMP microspheres, (c) microspheres exhibit polydispersion and (d) 
broken microspheres for EDS measurement.  
 
Figure 10.3 show micrographs of spheres used for elemental analysis by EDS. 2.67 % of nitrogen 
and 0.56 % of iron was detected in (a), single GMP sphere; and 1.03% of nitrogen and 1.36 % of 
iron in the collection of GMP microspheres. The existence of nitrogen was assumed to be from 
the encapsulated gentamicin (formula of Gentamicin, C21H43N5O7). However, the elemental 
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analysis by EDS is not quantitatively precise as discussed in the section 8.3.4 (Buck et al., 2004). 
Nevertheless, the results of EDS display the presence of nitrogen from the encapsulated GS and 
iron from encapsulated magnetite. Further accurate composition analysis of GMP can be 
undertaken by chemical method, for example, OPA assay.  
 
 
Figure 10.3 Elemental results of GMP microspheres at (a) single sphere and (b) 
collections of microspheres. 
 
In conclusion, the resultant morphologies of GMP particles have no obvious difference between 
the drugs free MP and the PCL microspheres. All spheres are spherical in shape and have a 
slightly rough surface. In addition, the GMP particles exhibited a polydispersed size distribution, 
which similar to the polydispersed PCL microspheres in Chapter 8. As discussed in section 8.3.1, 
the stabilizer was suggested to be a key point of size effects, which was confirmed by other 
reports of gentamicin-loaded PCL particles. The concentration and type of stabilizer play an 
important role in the size distribution of PCL and PCL composites (Chang et al., 2006; Blanco-
Prieto et al., 2002).   
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10.3.2 Encapsulation rate of gentamicin in GMP microsphere 
Loading efficiency is one of the important criteria for the development of a drug delivery system. 
The encapsulation efficiency of GS in GMP particles and its release were assessed using OPA 
fluorometric assay as described in section 10.2.1 (Gubernator et al., 2006).  
 
Table 10.1 shows the encapsulation loading and efficiency of GS within GMP microspheres. The 
concentration of PCL solution was obtained from the constant ratio (3 %) of the weight of PCL 
and the volume of dichloromethane. The initial loading rate of GS, 3.3 %, is calculated from the 
weight ratio of GS and PCL. To obtain the resultant GS loading rate, the formulated GMP 
particles were dissolved in dichloromethane and the encapsulated GS was extracted by PBS 
solution followed by determination by OPA assay. The weight ratio of encapsulated GS in the 
GMP microspheres was then calculated (fourth column in Table 10.1). The encapsulation 
efficiency was calculated by the weight ratio, which was the ratio that the actual encapsulated GS 
amounts and the initial loading GS amounts.  
 
Table 10.1 Drug loading efficiency of GS in GMP microspheres 
  
  PCL solution 
concentration 
(% w/v)  
Initial GS 
loading  
(% w/w) 
Resultant GS 
loading  
(% w/w) 
Encapsulation 
Efficiency  
(EE), (%)  
GMP2  3  3.3 2.12 ± 0.36 63.66 ± 11.00 
GMP6 3 3.3 3.28 ± 0.85 98.50 ± 25.53 
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According to GS determination by OPA assay, the results in Table 10.1 indicated the successful 
of encapsulation of GS within the MP microspheres. GMP6 microspheres were found to have 
more GS loaded and therefore higher EE value than GMP2 microspheres. The production of GS 
loaded PCL relies on the sufficient adhesion offered by the polymer. Raising the viscosity of the 
polymer is necessary for to avoid phase separation under gravity, such as encountered in the 
centrifugation process (Chang et al., 2006
2
). The viscosity of PCL2 (480 mPas at 60 °C) is 
approximately 20 times lower than the viscosity of PCL6 (9300 mPas at 100 °C) as shown in 
Table 8.1. The relatively low EE rate of GMP2 was assumed to be from the lower viscosity of 
PCL2 which has less ability to entrap the drug during formulation. In addition, the highly 
hydrophilic GS tends to lead into the water phase during solvent evaporation in the GMP 
formulation (Naraharisetti et al., 2005). The combination of low viscosity of PCL2 and the 
hydrophilic GS leads to the relative low encapsulation rate of GS in GMP2.   
 
10.3.3 AMF treatment and drug release 
To the achievements that MP particle softened by magnetite heating in the uniformed AMF and 
the successfully synthesised GMP microsphere, inducing of drug release by the AMF treatment 
was carried out. The release of GS has three major release stages, burst release of rapid diffusion, 
swelling of shapes and hydrophilic behaviour of GS and finally, gradual release as a result of 
polymer degradation (Silva et al., 2007). The values of GS release were determined by the weight 
ratio (μg/mg) of GS to GMP, by the cumulative release rate and the release amount by daily 
evaluation. The GS release presented by weight ratio can be easily applied to dosage evaluation 
for in vitro and in vivo study in the future.   
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In Figure 10.4, the GS amounts released from GMP2, exhibit the burst release in the first three 
days after AMF treatment, the release amounts were approximately 80 μg/mg. After the burst 
release phase, the cumulative curve indicates an incremental release trend, between days 3 and 7, 
prior to reaching the plateau region, after 7 days maintained at 37 °C. The GS release after one 
week, from days 8 to 10, is shown by plateau region of the cumulative release and implies was 
drug release. 
 
 
Figure 10.4 GS release from GMP2 spheres after AMF treatment immersed in 
PBS at 37 °C for periods up to 10 days (n = 6, mean ± SD).  
 
The GS release from GMP6 is shown in Figure 10.5. Similar to the results of the GS released 
from GMP2, the amounts of the released GS in the first two days were relatively higher than the 
release amounts in the following week. By contrast, the first day release of GS from GMP6 was 
approximately 100 μg/mg which was much higher than the value of GMP2 (80 μg/mg). In 
addition, the cumulative release curve of GMP6 indicated that the first two release stages of 
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GMP6 tended to finish on day 8 but still showed higher values than the GS release from GMP2 
released GS at that stage. 
 
 
Figure 10.5 GS release from GMP6 spheres after AMF treatment immersed in 
PBS at 37 °C for periods up to 10 days (n = 6, mean ± SD). 
 
A major burst release of GS from GMP2 and GMP6 can be observed in the first 3 days, as seen in 
Figure 10.4 and Figure 10.5, respectively. In comparison to the results of GMP2 microspheres, 
GMP6 microspheres released more GS in the initial burst state and at the end of the first two 
release stages. This assumed to be or the higher encapsulation rate of GS in resultant GMP6 
particles (Blanco-Prieto et al., 2002; Virto et al., 2003). 
 
To further understand of the influence of AMF on drug release profile, GS released from GMP2 
and GMP6 microspheres without AMF treatment were investigated at 37 °C. In Figure 10.6, the 
first burst phase lasted the first two days for GMP2, which is similar to AMF-treated results, but 
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the value of burst release was much lower. There was 45 μg/mg of GS released on the day zero of 
the in vitro assay, which was almost half the value of the GS released from AMF-treated GMP2 
and GMP6 (80 μg/mg and 100 μg/mg respectively). The release behavior displayed a gradual 
reduction in the amount of GS, which maintained prolonged release after 8 days and will still had 
a GS release value of approximately 18 μg/mg. The GS value for the plateau region was stable at 
60 μg/mg as by, which is also almost half the value of the AMF-treated GMP2.  
 
 
Figure 10.6 GS release from GMP2 spheres and immersed in PBS at 37 °C for 
periods up to 10 days (n = 6, mean ± SD). 
 
GS release results for non-AMF treated GMP6 are shown in Figure 10.7. The first burst phase 
still occurred on the first two days, and the value of burst release stage was similar to the value of  
non-AMF treated GMP2 (Figure 10.6). The values of the cumulative release once the time period 
also indicated a slow release of GS, GMP6 microspheres still showed the ability to release GS 
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approximately 13 μg/mg after 9 days at 37 °C storage, which was higher than AMF-treated 
GMP6 and GMP2 and non-treated GMP2 particles at the same time point. The GS value of the 
plateau region (approximately 65 μg/mg) was slightly higher than the value of GMP2 (Figure 
10.6), but was lower than the value of GS released from the AMF-treated GMP microspheres.  
 
 
Figure 10.7 GS release from GMP6 spheres immersed in PBS at 37 °C for 
periods up to 10 days (n = 6, mean ± SD). 
 
GMP microspheres with AMF treatments had more GS released in the burst stage, and the AMF-
treated GMP6 microspheres released more GS than AMF-treated GMP2 microspheres due to the 
higher EE rate. It is interesting to note that the burst release value for GS from non-AMF treated 
GMP6 and GMP2 microspheres were similar, but in the slow release stage (the plateau region) 
GMP6 released more GS. By contrast to GMP2 microspheres, the GMP6 microspheres had 
greater GS encapsulation efficiency and exhibited more GS released during the first release stage 
 136 
after AMF treatment, but the non-AMF treated GMP6 microspheres showed more GS release at 
in the second stage of release. This confirms that microspheres containing more drug resulted in 
higher release rates as shown in Figure 10.5. 
 
To conclude, the increasing GS release prior to the plateau stage is suggested to be due to GS 
close to the polymer surface, which was extracted by water during phase immersion due to the 
hydrophilic nature of GS (Silva et al., 2007). The final release stage as a result of polymer 
degradation cannot be seen in the ten day period as the degradation time of PCL is relatively long, 
which can be from weeks up to years, as reviewed in Chapter 3. AMF treatment was assumed to 
increase the first stage of burst release and the rapid diffusion of GS to the PBS solution. AMF 
treatments caused damage to the polymer (as shown in Figure 9.9 and discussed in the section 
9.3), as a result of by magnetite heating and resulted in a higher permeability of GS in the 
immersed solution.  
 
There was no notable difference in the burst release of GS from non-AMF treated GMP2 and 
GMP6 microspheres. Virto et al have reported that for in vitro testing in a highly hydrophobic 
polymer, the entrapped antibiotics will not be entirely released out (Virto et al., 2003), therefore, 
the drug release induced by the magnetite heating in the AMF is advantageous for enhancing the 
release of encapsulated drugs. 
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10.3.4 Effects of storage at different temperature on the GS  
The storage condition of GS is ather factor to consider to maintain the drug activity and 
remanence. The efficacies of GS were undertaken using the GS buckl solution (0.1 μg / ml) for 
two storage conditions, 4 °C and 37 °C. The GS solution preserved at 4 °C maintained drug 
activity after storage for one month as shown in Figure 10.8, whereas the GS solution at 37 °C, 
exhibited a reduction in activity after 5 days. Although, gentamicin is reported as a thermally 
stable antibiotic(Casemore, 1967), the drug activity decreased to half after 32 days at 4 °C and 6 
days at 37 °C. The activity reduction of GS can be another factor or the reduction of GS from 
both the AMF-treated and non-treated GMP microspheres after a week in the PBS solution at 37 
°C.  
 
  
Figure 10.8 Temperature effects on GS activities. Gentamicin concentration of 
0.1 μg/ml PBS at 4 °C and 37 °C for 37 days and 10 days respectively. 
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10.3.5 Microbiology activity test 
The GMP loaded microspheres were shown to successful release of GS, and the efficacy of the 
GS was assessed on a bacterium. The first day release of GS from non-treated GMP microspheres 
and AMF-treated GMP microspheres was used to observe its effects on the inhibition zones 
formed by E. coli. The zone size of the control specimen (GS solution alone) was used as a 
standard for comparison. The zone size is the ratio of the diameter of the zone of inhibition and 
the diameter of the plate. In Formula 10-1, DC is the diameter of the inhibition zone of the control 
and DP is the diameter of the plate. The resultant zone areas of GMP microspheres with or 
without AMF treatments were compared. The zone size was the ratio of Zone diameter and ZoneC 
as is calculated by Formula 10-2.  All the diameters of the inhibition zones were measured by 
Image J software and the statistical values are shown in Table 10.2. Group A is for GS released 
from non-treated GMP microspheres using an E. coli culture concentration of 1.55 x 105 CFU/ml. 
Group B and C are for he studies of the microbiological activities of the GS antibiotic for AMF-
treated GMP microspheres. The concentration of E. coli culture for group B and group C were 1.3 
x 104 CFU/ml and 4 x 105 CFU/ml, respectively. 
 
        (    ⁄ )                                  10-1 
            
(      )⁄
     
                                    10-2 
 
The control specimen (GS stock solution preserved at 4 °C) represented the maximum 
antibacterial ability for all three groups. The ratio of inhibition zone size was almost constant at a 
value of approximately 10. In group A, the GS concentration of the control specimen was 0.7 μg / 
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μl, and both the GS release amount from GMP6 and GMP2 microspheres was 0.02 μg / μl, as 
shown in Table 10.2. The released GS from GMP6 microspheres exhibited drug activity and gave 
a zone size ratio of 4.4. However, the released GS from GMP2 microspheres had the same initial 
amount of GS but did not maintain drug activity. After the AMF treatments, the GS released from 
both GMP2 and GMP6 microspheres was slightly higher (0.04 μg/μl to 0.03 μg/μl) than non-
AMF treated GMP microspheres as seen in the results for group B and group C.  
 
Furthermore, GMP2-released GS displayed antibacterial activity and gave an inhibition zones a 
ratio of 3.5 for a bacterial culture with lower concentration (1.3 x 104 CFU/ml). On the other 
hand, for the same concentration (0.04 μg / μl) of GS released from GMP2 microspheres the drug 
activity could not maintain for the higher concentration of bacterial culture (4 x 105 CFU/ml). 
The GMP6-released GS exhibited drug efficacies and the inhibition zones of E. coli were 
demonstrated for the two concentrations of cell culture for 1.3 x 104 CFU/ml and 4 x 105 
CFU/ml, respectively. The GS concentration released from the AMF-treated GMP6 (0.03 μg / μl 
and 0.04 μg / μl, group B and C) was almost half of the GS values of the control specimen (0.06 
μg / μl), and therefore the inhibition zones obtained were approximately half of the ratio of the 
control.       
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Table 10.2 Inhibition zones of GMP microspheres from with or without AMF 
treatment. 
 
A Non treatment / 1.55 x 10
5 
CFU/ml 
 Control GMP6 GMP2 
GS (μg/μl) 0.07 0.02 0.02 
Zone area (ratio) 10 ± 0.1 4.4 ± 0.0 0.0 ± 0.0  
B AMF Treated / 1.3 x 10
4
 CFU/ml 
 Control GMP6 GMP2 
GS (μg/μl) 0.06 0.03 0.03 
Zone area (ratio) 10 ± 1.1 4.4 ± 0.2 3.5 ± 0.3 
C AMF Treated / 4 x 10
5
 CFU/ml 
 Control GMP6 GMP2 
GS (μg/μl) 0.06 0.04 0.03 
Zone area (ratio) 10 ± 1.4 4.9 ± 0.3 0.0 ± 0.0 
 
 
The inhibition zones of E. coli at a cell concentration of 4x105 CFU/ml exhibited after the 
incubation at 37 °C for 24 hours, shown in Figure 10.9. In Figure 10.9, (a) shows the inhibition 
zones obtained from the cell culture (4x105 CFU/ml) for the control specimen (0.06 μg/μl of GS), 
(b) shows the resultant inhibition zones (4.9, 0.04 μg/μl) for the AMF-treated GMP6 
microspheres and (c) shows the inhibition zones (0,  0.03 μg/μl) from a E. coli culture (1.3 x 104 
CFU/ml) for  the AMF-treated GMP2 microspheres.   
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Figure 10.9 Inhibition zones of E. coli shown after 24 hours incubation by (a) 
0.06 μg/μl Gentamicin (control specimen), (b) 0.03 μg/μl GMP6 microspheres 
and (c) 0.03 μg/μl GMP2microspheres. 
 
GS from the burst release phase of the GMP microspheres displayed bactericidal activity against 
E. coli and was concentration dependent on both the bacterial culture and the drug loading.  
 
The effects of aminoglycoside antibiotics against microorganisms have been investigated. The 
clinically important aminoglycoside, gentamicin, is able to bind directly to ribosomal RNA and 
cause decrease in translation and inhibit translocation of the ribosome of bacterial (Yoshizawa et 
al., 1998, Casemore, 1967). For both AMF-treated and non-treated GMP microspheres, the 
inhibition zones of E. coli indicated the resultant GMP microspheres maintained the efficacy of 
the released GS.   
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10.4 Conclusion 
According to the morphologies of the GMP particles, the loading GS did not exhibit significant 
effects on the shape and size of microspheres in the compares of MP particles. The results of 
elements analysis indicated the success of GS encapsulation in MP particles due to the presence 
of nitrogen (shown in Figure 10.3), and which was further confirmed by the evaluation of GS by 
the OPA assay, as seen in Table 10.1. Consequently, the formulated GMP microspheres were 
placed in the uniformed AMF with the identified condition (Chapter 9), which was followed by 
the study of drug release and morphology observation.  
 
As expected, the AMF-treated specimen showed higher GS release rates then non-treated 
specimen, which were 80 μg/mg to100 μg/mg and 45 μg/mg of the release amounts on the day 
zero.  Moreover, the encapsulation rate was suggested to be affected by the viscosity of polymers, 
which is expectably resulted in higher value of drug release (Chang et al., 2006). As discussed in 
the section 10.3.2, there were more GS encapsulated within the GMP6 (98.50 %) than the GMP2 
(63.66 %) particles while the loading amount of GS is constant, and the viscosity of PCL6 is 
approximately 20 times higher than PCL2. Finally, the released GS demonstrated the drug 
efficacy by the inhibition zones formed by E. coli, shown in Figure 10.9. The AMF-treated 
magnetic polymers offer a new method for drug release of wound healing and cancer treatments. 
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Chapter 11 Conclusion and Future work 
 
Material and properties 
This research is focused on two major sections, production of magnetite nanoparticles and MP 
microspheres; and the application of the latter to bone replacement. Both magnetite and PCL can 
be produced in different sizes ranges. Magnetite and PCL were successfully combined to form 
MP microspheres. The two types of PCL microspheres produce in a regular spherical shape at 
different mixing conditions. The micro-CT X-ray images show two major densities in the MP 
sample indicating that magnetite has been incorporated into the PCL microspheres. This will be 
used for further research into the rheology and magnetic properties of the melted MP compounds.  
 
Coating agents bring some benefits for magnetite particles, like protection from particles 
adhesions, controlling pH values and ionic strength and functionalised (Tombacz et al., 2006). 
This may be a great idea, which can be implemented in this study, in the emulsification process 
of magnetite nanoparticles into PCL, and the particle of MP could be used in further applications 
such as drug delivery and target adhesions; however much more work would need to be done in 
this area. In addition, magnetic device for magnetite selecting could reduce the undesired 
particles, such as oxidised or lower magnetic saturation; which could guarantee uniform and 
narrow distribution of magnetic particles for further applications. 
 
MP microspheres can be synthesized into different types of biomaterials by different formation 
methods with other polymers, such as sponges and scaffolds. Moreover, the research will 
investigate the incorporation of different bone materials, for instance, hydroxyapatite and β-TCP, 
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which enhance the architectural substitute. Polymer and ceramics composites with magnetite 
offer the degradable scaffold (polymer) for drug delivery and the sustained structure (ceramics) 
for bone replacements and tissue engineering. Magnetite containing brushite was reported having 
ability of hyperthermia of killing cancer cell and without normal cells damaging (Hou et al., 
2009).  Moreover, this ceramic composite has been used for drug delivery (Habraken et al., 2007) 
 
In addition, multi-domain magnetic particles (not pure magnetite) shows greater rate of specific 
loss power, which has a result of much heating generated. This provides an efficient method for 
hyperthermia. For example, after AMF treatment for 15 minutes (at 7 mega Hz), the ferrite 
particles, BaFe12O19 and SrFeO19 had temperature increasing rate (∆T) of 47.6 K and 62.7 K, 
both were higher than the ∆T of magnetite, 4.3 K (Kim et  al., 2005).  
 
Moreover, the thermal behaviour of magnetite nanoparticles and MP microspheres were measure 
by DSC with a heat rate of 10 ºC/min. Slowing done the heat rate from 10 ºC/min to 1 ºC/min 
might be an idea to the observation of thermal conductivity between nanomagnetite and 
surrounding PCL. 
 
Thermal treatments with alternative magnetic fields 
Because the magnetite nanoparticles can be encapsulated into PCL, which showed good 
dispersion inside the microspheres, it is expected to generate heat to surrounding PCL. Heating 
with a microwave indicated that heat can be transferred to the PCL which cause it to melt. That 
can supply magnetism to rotate the encapsulated magnetite inside the microspheres and induce 
melting. However, microwave is not the ideal treatment in vivo due to the well-known 
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harmfulness to normal cell and tissue. Therefore, heat treatment by an alternating magnetic is a 
growing need for the development of hyperthermia in clinics. 
 
Most of the AMF for hyperthermia experiments were using laboratory-made generators with 
altered frequency and magnetic fields amplitudes. The frequency scan is technically tricky due to 
the terms of frequency-dependent effects and resistance of magnetic applicators (Mornet et al, 
2004; Ohno et al., 2002). Full-szed human prototypes have been built (shown in Figure 4.3) is 
clinical using for hyperthermia. Isolating or vacuum system should be used upon AMF treatment 
to reduce the temperature diffusion in the ambient environment (Kim et al., 2005), which would 
bring benefits of efficient temperature monitoring during the process and heat conducting 
between particles for lower production cycle of soften MP. AMF is generated by a 3 loops coil 
and water cooling system. Power generator with high power and frequency (approximately 300 
kHz) can be employed to soften larger amounts of MP particles and can perform a stronger field 
for trauma model in a wider air gap. The gap between metal cores was designed for loading more 
samples and bone defects model for the future work.   
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Chapter 12  Appendix 
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 Appendix 12.2 Details of the AMF                                                  (R. Dickerson) 
 
Power Supply 2. 
This is a high performance power supply. Its current is directed to the core via the inverter. It is 
capable of providing up to 30 A at 100 V DC, and it practiced is used up to 80 V. The refinement 
of the power supply has meant it is able to cope with the intermittent load provided by the set up. 
 
Power Supply 1. 
This provides a 12V DC source for the electronics in the inverter. It is regulated down to 5 V DC. 
It is easier to use an extra power supply than it is to reduce 100 V DC to 5 V DC. 
 
Oscilloscope 1. 
This is connected to the sync output of the inverter. The sync port provides a simpler square wave 
output at the same frequency as the core current. This allows the use of the frequency readout 
facility in ‘scope 1 to quickly show the actually frequency of the inverter. 
 
Oscilloscope 2. 
This reads the output of a current clamp attached to one of the core cables. The clamp has no 
electrical contact, but can still read and plot the waveform of the current on ‘scope 2. This is used 
to take RMS and peak current readings, and confirms the inverter is functioning properly. 
 
Inverter 
The inverter is a low cost solution which can be programmed to create AC voltages from Power 
Supply 1 by switching the polarity of its output at a frequency specified by the laptop. The 
voltage coming out of the inverter is dictated by Power Supply 1.The inverter is based around a 
microcontroller with a program embedded in it. The microcontroller control the switching of 
MOSFET transistors in an H-bridge configuration in order to create the AC. The frequency at 
which the inverter functions is dictated via the inverter’s internal crystal (running at 10 MHz) and 
a variable embedded in the program. For simplicity of development, there is no facility for 
changing the frequency of the inverter without a programming interface and a copy of the 
original program.The PIC microcontroller contains a continuously running timer in the form of 
an incrementing number. Every time this number reaches that of the variable, the PIC steps 
through one of the four configurations the MOSFETs need to be in to create the AC waveform. 
The timer is then reset. 
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Laptop 
The laptop is used to interface with the Inverter and IR temperature sensor. For the inverter, the 
laptop programs the frequency of the pulses. Downloading the new program and frequency onto 
the PIC microcontroller in the inverter requires a programming interface (PICKit2 in this case), 
the C18 compiler, a development environment (MPLAB in this case) and a copy of the original 
program. Once programmed, the inverter can work without the laptop. For the remainder of the 
experiment, the laptop is used to log data from the IR sensor. 
 
Gauss Meter 
The gauss meter reads the strength of the magnetic field. The probe itself is thin, allowing it to be 
inserted into the gap in the core. The meter gives the RMS value of the field in the core. This is 
used to ensure any voltage/frequency combination is not producing a field which is pointlessly 
small. 
 
Thermocouple readout 
This monitors the temperature of two thermocouples. Once is mounted on the core close to the 
sample, the other to the coil of wire. This is used to assess whether heat in the sample is coming 
from the AC magnetic field, or from resistive losses in the coil. 
 
Inverter program interface 
This small using is used to allow the laptop to program the PIC microcontroller in the inverter. 
 
Resistor (not in figure) 
A resistor capable of high power dissipation is used for the testing of the inverter. It has no 
inductive characteristics meaning the current flow is exactly the same as the voltage applied. This 
allows easy testing of the inverter during the development stages, but has no role in the actual MP 
experiments. 
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Appendix 12.3 Calibration curve of Gentamicin release by OPA assay. 
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